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ABSTRACT 
Angiotensin converting enzyme (ACE) inhibitors are becoming increasingly 
important in management of hypertension and related cardiovascular diseases. The 
prevalence of these diseases is increasing dramatically in Chinese populations as 
their life-styles become more affluent and "Westernised". However, although 
increasingly large numbers of Chinese are being treated with ACE-inhibitors, the 
pre-clinical and clinical evaluations of these drugs are almost entirely in non-
Chinese populations. There is evidence of ethnic differences in the response to 
other types of drug such as propranolol and warfarin, and the incidence of cough 
with ACE-inhibitors appears higher in Chinese. Some recent studies have 
suggested that certain ACE-inhibitors are less effective in Chinese than 
Caucasians, particularly if not combined with a diuretic. The aim of the studies 
in this thesis is to compare the oral single-dose pharmacokinetics and 
pharmacodynamic responses to two novel prodrug ACE-inhibitors，perindopril 
(Sender International) and cilazapril (F. Hoffmann La Roche Pharmaceuticals), in 
healthy, normotensive Chinese and Caucasian volunteers. The plasma half-life of 
perindopril being longer than cilazapril. 
The pharmacokinetic parameters of perindopril were compared after a 
single oral dose of 4 mg and a weight-adjusted dose of 4 mg/70 kg, fourteen days 
apart. The pharmacokinetics of cilazapril were compared after a single, oral dose 
of 2.5 mg. Plasma was sampled for both the prodrug, its active metabolite, 
plasma renin and ACE-activity, aldosterone and angiotensin I concentrations. 
Sampling continued at intervals to 96 hours post-perindopril administration, and 
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to 72 hours post-cilazapril. Urine was sampled in timed collections throughout 
each study period for measurement of the prodrug and the active metabolite. 
Assessment of haemodynamic changes was achieved through automated recording 
of blood pressure and heart rate up to 24 hours post-perindopril and to 72 hours 
post-cilazapril. Transthoracic electrical bioimpedance cardiography (TEB) with 
the NCCOM3-R7 non-invasive haemodynamic monitor was used to assess beat-to-
beat changes in haemodynamics both before and after drug administration on each 
study day. 
We found no evidence to suggest that the recommended dosage of either 
drug should be altered in Chinese populations. However, the t^^ of perindopril 
was significantly shorter in Chinese subjects after the 4 mg dose, perhaps 
suggesting faster absorption of the prodrug. The tendency remained after 
administration of the weight-adjusted dose, but did not reach significance. 
Equivalent data for cilazapril was not available, being withheld by F. Hoffmann 
La Roche. In addition, certain differences in the pharmacodynamic responses to 
ACE-inhibition were found between the two ethnic groups. There was a more 
prolonged reduction in diastolic blood pressure in Caucasian subjects, and a 
significant rise in heart rate in Chinese subjects. Moreover, the increase in 
systolic blood pressure in response to standing was abolished in Chinese subjects 
after cilazapril, perhaps indicating an alteration in pressor responses. The 
existence of a genuine difference between Chinese and Caucasians in the 
antihypertensive response to ACE-inhibitors is a real possibility which requires 
further, more intensive research. 
3 
Introduction 
Antihypertensive medications are predominantly evaluated in Western 
Caucasian populations. However, ethnic differences in pharmacokinetics and 
pharmacodynamics are known to exist, especially when individuals of black 
African origin are compared with white. In fact, a plethora of causative 
mechanisms for racial differences in the pharmacokinetics and pharmacodynamics 
of certain drugs have been documented. With regard to Chinese populations, 
which represent in excess of three thousand million individuals, remarkably little 
is known regarding possible ethnic differences with Caucasians. Although some 
isolated studies have reported differences, such as with propranolol (Zhou et ah， 
1989) and warfarin (Chan, Tsoi & Critchley，1992). ACE-inhibitors have a 
steadily increasing role in cardiovascular therapeutics, and at the present time no 
ethnic differences in pharmacokinetics have been reported between Chinese and 
Caucasians. However, an increased incidence of cough has been demonstrated in 
Chinese subjects given ACE-inhibitors as compared to the accepted norm in 
Caucasians (Chan, Chan, Luk, Leung, Li & Critchley; 1993) and this may be due 
to racial differences in pharmacokinetics. In addition, enalapril has been shown 
to be less effective in blood pressure among Chinese diabetic patients in 
comparison with other data obtained in Caucasians (Chan, Cockram, Nicholls, 
Cheung & Swaminathan; 1992). ACE-inhibitors have also been shown to be less 
effective in black South African patients (Seedat & Parag，1987). 
In view of the growing popularity of ACE-inhibitors in the treatment of 
hypertension, it is important to establish the pharmacokinetics and 
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pharmacodynamics of these agents in such a large ethnic group as the Chinese. 
Two of the newer ACE inhibitors are perindopril and cilazapril and both were 
developed in Europe. As a result, most of the knowledge of their pharmacokinetic 
and pharmacodynamic effects was gained in Caucasian volunteers. This meant 
that comparative pharmacokinetic and pharmacodynamic studies were particularly 
important in association with their respective launches onto the Asian markets. 
We planned to compare the oral, single dose pharmacokinetics of cilazapril 
and perindopril between groups of Chinese and Caucasian healthy volunteers, 
based on radioimmunoassay of plasma and urine samples. Acute 
pharmacodynamic responses to the ACE-inhibition were estimated by transthoracic 
electrical bioimpedance cardiography, a non-invasive method for continuous 
monitoring of cardiac output and other related haemodynamic parameters. The 
conventional measurements of plasma ACE-activity, renin-activity and aldosterone 
concentrations as well as blood pressure and heart rate were also performed. 
5 
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Literature Reviews 
Pharmacoanthropology and Pharmacogenetics 
"The investigation of populations and their differences is a study not only of 
medicine, but of human biology’ which brings pharmacology and toxicology into 
contact with the previously remote principles of anthropology and population 
genetics. “ (Kalow, 1982). 
The above quotation aptly describes the comparatively new field of 
pharmacoanthropology. Pharmacoanthropology can be defined as the study of 
interethnic variation in the pharmacokinetics of drugs (Kalow, 1984). It is a 
subject complicated by almost every aspect of daily living. Food (Anderson, 
Conney & Kappas，1979), the smoking of cigarettes (Cooksley, Farrell, Cash & 
Powell, 1989)，the contraceptive pill (Mucklow, Fraser, Bulpitt, Kahn, Mould & 
Dollery, 1980) and exposure to environmental toxins (Kalow, 1982) can all 
influence an individual's ability to metabolize certain xenobiotics. Most of these 
factors vary between ethnic groups, with diets and nutritional state differing widely 
between countries as does environmental pollution. The use of insecticides 
changes with economic development and the type of pests encountered, while the 
use of such drugs as tobacco and the contraceptive pill is mediated by social and 
religious taboos. The matter is further compounded by a variety of genetic 
differences, the incidence of which shifts among different populations. 
In many countries vegetables are eaten more frequently than meat, and in 
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some, religious beliefs impose a vegetarian diet. Thus diet must be included in 
any consideration of ethnic differences in drug metabolism and has been shown to 
have some interesting effects on pharmacokinetics. Kappas, Alvares, Anderson, 
Pantuck, Pantuck, Chang, & Conney (1978) found that the mean plasma half-lives 
of antipyrine and theophylline were each decreased by 22% after subjects were fed 
a high protein diet, containing charcoal-broiled beef. Metabolism returned to 
normal when the subjects were fed a normal diet. 
Anderson et al (1979) examined the effects of diets high in fat, protein or 
carbohydrate on the rate of metabolism of antipyrine and theophylline. They fed 
their healthy subjects on a solid diet in which they altered the content so as to be 
high in fat, carbohydrate or protein. They found that the substitution of 
carbohydrate with equivalent calories of fat had little effect on the kinetics of 
either drug, nor did the substitution of fat with carbohydrate, even after 10 to 14 
days on the respective diets. However when the diets were made high in protein 
content, the metabolism rate of both drugs significantly increased, as shown by the 
decrease in the half-life of both drugs by more than 15%. 
Mucklow et al (1980) examined the factors effecting paracetamol 
metabolism in London factory and office workers. They found that the clearance 
of paracetamol was faster in meat eating subjects compared to vegetarians. 
However this data is hard to interpret as nearly all their vegetarian subjects, were 
of Asian decent whilst most of the meat eaters were Caucasian. Therefore the 
effects of diet cannot be separated from those of ethnic origin. 
The above studies have shown that a high protein diet can increase the 
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metabolic activation of certain drugs. However, certain vegetables are also 
capable of altering drug metabolism. Pantuck, Pantuck, Garland, Min， 
Wattenberg, Anderson, Kappas & Conney (1978) showed that a diet high in 
brussel sprouts and cabbage can also have a stimulatory effect on drug 
metabolism. 
Cigarette smoking and the ingestion of alcohol have been shown to 
influence pharmacokinetics and the use of both these agents shows considerable 
interethnic variation, especially in women. Mucklow et al. (1980) found that 
paracetamol clearance increased with increasing alcohol intake and cigarette 
consumption. The effect of cigarette smoking was explained by the fact that it 
contains polycyclic hydrocarbons which are hepatic enzyme inducers. The use of 
alcohol has been shown to induce microsomal enzymes in man (Vesell, Page & 
Passananti, 1971). 
1.1.1 Genetic Polymorphisms 
Perhaps the most proliferative work in this field of late has been done in 
the area of genetic polymorphisms. The study of such variations in drug 
metabolising ability has been termed pharmacogenetics, i.e. "study of the influence 
of hereditary factors on the response of individual organisms to drugs" (Taber's 
Cyclopedic Medical Dictionary, 15th Edition). These can readily be classified into 
two major types, oxidative polymorphisms and acetylation polymorphisms. 
However, a variety of other genetic variations exist, such as in levels of aj-acid 
glycoprotein. It is beyond the scope of this thesis to discuss all the polymorphisms 
that exist, but a review of these major types is essential for an understanding of 
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the subject. 
The rate of metabolic oxidation in the liver is an important determinant of 
interindividual variations in the pharmacokinetics of many drugs (Horai & 
Ishizaki, 1988). The oxidation polymorphism consists of two phenotypes, poor 
metabolizers (PMs) and extensive metabolizers (EMs). From a clinical standpoint, 
this generally means that patients with the PM phenotype are more likely to 
develop adverse effects to certain drugs while EMs may have a reduced 
therapeutic reponse to them (Horai et al, 1988). A number of different enzymes 
can be involved, including N-acetyltransferase (Adam, Rogers, Amiel & Rubens， 
1984)，paraoxonase (LaDu & Eckerson 1984)，alcohol and aldehyde 
dehydrogenases (Yoshida, 1982) and pseudocholinesterase (Kalow & Genest， 
1957). Recent work has identified several specific categories of genetically 
determined polymorphisms in drug oxidation reactions, affecting a wide variety 
of drugs (Horai & Ishizaki, 1988) and it is likely that many more have yet to be 
discovered. A tentative list of those identified so far reads as follows :-
• Debrisoquin/sparteine oxidation (Eichelbaum, Bertilsson, Sawe, & 
Zekhom, 1982) in relation to metoprolol oxidation (Lennard, Silas, 
Freestone, Ramsay, Tucker & Woods, 1982) 
• Sulfoxidation of S-carboxymethyl-L-cysteine (Waring, 1988) 
• S-mephenytoin hydroxylation (Nakamura, Goto, Ray, McAllister, Jaqz, 
Wilkinson & Branch, 1985) 
• Nifedipine oxidation (Kleinbloessem, Van Brummelen, Faber, Danhof, 
Vermeulen & Brcimer，1984; Ahsan, Renwick, Macklin, Challenor, 
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Waller，& George, 1991) 
• Phenytoin hydroxylation (Steiner, Alvan, Garle, Maguire, Lind, Nil son, 
Tom son, McClanahan & Sjdqvist，1987) 
• Tolbutamide hydroxylation (Scott & Poffenberger, 1979) 
Each of the above polymorphisms can effect the metabolism of several 
drugs，with the exception of that of S-mephenytoin，which is only known to effect 
one, mephobarbital (Horai & IsMzaki，1988). They arise from genetically 
inherited differences in the metabolic functions of the isozymes of the cytochrome 
P450 system, whether quantitative or qualitative (Jacqz, Hall & Branch, 1986). 
Much of data on this phenomenon has been gathered with two drugs, sparteine and 
debrisoquine. Sparteine has the potential to cause severe side-effects. These 
adverse effects were correlated by Eichelbaum et al, 1982 with high plasma 
concentrations of the drug and low recovery of the two main hydroxylated 
metabolites in the urine. Determination of phenotype was made by giving a fixed 
dose of sparteine and dividing the amount excreted as the parent drug by the 
amount excreted as the hydroxylated metabolite, i.e. the metabolic ratio. A 
similar method is used to identify PMs of other drugs. Using this equation, they 
identified PMs of sparteine as having a metabolic ratio of over twenty. 
It was at around the same time that researchers in Great Britain discovered 
a genetically related deficiency in the hydroxylation of debrisoquine. Mahgoub, 
Idle & Dring (1977) found that 9% of a sample population exhibited an impaired 
ability to metabolise debrisoquine to 4-hydroxydebrisoquine (its main metabolite) 
and also 5-, 6-, 7-, and 8-hydroxydebrisoquines (lesser metabolites). Shortly after 
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tat，the PM phenotype for sparteine and debrisoquine were found to be closely 
linked, i.e. PMs of sparteine were found, in most cases to be PMs of 
debrisoquine, however this is not the case in about 3% of British subjects (Kalow, 
1982). 
The incidence of the debrisoquine PM phenotype varies between races. 
Table 1.1 gives a summary of the incidence in various populations. However, 
caution must be exercised when attempting to interpret such figures as it is thought 
that the same Cytochrome P450 isoenzymes may not be responsible for the 
metabolism of debrisoquine or sparteine in all races (Horai & Ishizaki，1988) and 
some may have dual specificity. In addition, test protocols vary widely. This 
particular polymorphism has been shown to affect the metabolism of over 20 other 
drugs, making it an important tool for determining a "high risk" group of patients 
when wishing to evaluate their safety. A great many pharmacokinetic studies have 
been conducted, using PMs of debrisoquine as a study population. 
Table 1.1: The incidence of the debrisoquine poor metaboliser phenotype in 
various populations. 
Investigators Race Incidence 
Zhou et al (1989) Caucasians 8-10% 
Horai & Ishizaki (1988) Egyptians 1 % 
Lou et al (1987) Chinese 0.7% 
Nakamura et al (1985) Japanese ^ 
Another important genetic polymorphism lies in the N-acetylation capacity 
of some individuals, and has been recognised for over 20 years (Clark, 1985). 
The enzyme acetyltransferase, in its various forms, is involved in the metabolism 
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of a wide variety of drugs such as isoniazid, procainamide, hydralizine, dapsone, 
sulphamethazine, some other sulphonamides and some putative carcinogenic 
arylamines (Horai, Zhou, Zhang & Ishizaki，1988). However, as not all forms 
of acetyltransferase are affected by this particular trait, not all drugs that undergo 
acetylation are affected either. Like the debrisoquine/sparteine phenotype, the 
acetylator phenotype can also be classified into two groups, slow acetylators (SAs) 
and fast acetylators (FAs). Table 1.2 gives the incidence of the fast acetylator 
phenotype in various populations. Many therapeutic consequences have been 
linked with both the SA and FA phenotype. For example, when treated with 
isoniazid for tuberculosis, the SAs may be more prone to develop systemic lupus 
erythematosis (SLE) or peripheral neuropathy, even on standard doses. FAs have 
a poorer therapeutic response when treated for pulmonary tuberculosis (Clark, 
1985). An investigation by Mitchell, Thorgeirsson, Black, Timbrell, Snodgrass, 
Potter, Jollow & Keiser (1975) reviewed patients who had previously developed 
hepatitis whilst on isoniazid therapy, they found that this condition developed more 
frequently in rapid acetylators than in slow acetylators. Isoniazid is metabolised 
to acetylhydrazine which can have hepatotoxic effects, the authors suggest that 
FAs may be exposed to a higher concentration of this metabolite and therefore 
more likely to suffer damage to the liver. 
Table 1.2: The incidence of the fast acetylator phenotype in various populations, 
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Another possible source of inter-racial variation in pharmacokinetics is the 
level of plasma binding proteins. In 1975, the importance of the hitherto little 
noticed a「acid glycoprotein (AAG) was accidentally brought to light. Two 
English investigators (Gotham & Shand, 1975) noticed unusually low plasma 
propranolol concentrations in samples collected into vacutainers, this was 
subsequently found to be due to a chemical in the rubber stopper (Tris-butoxy 
ethyl phospate) which displaced the propranolol from it's binding site on AAG. 
Subsequent studies have shown that AAG is the major binding site of many basic 
drugs (Routledge, 1986). Not only do the levels of this glycoprotein vary in 
health and disease, but also between ethnic groups. Zhou, Adedoyin & Wilkinson 
(1990) examined the differences in plasma protein binding of warfarin, diazepam, 
salicylic acid, diphenhydramine, propranol and disopyramide in Chinese and 
Caucasians. They found no difference in the plasma levels of albumin between 
the 2 groups and therefore no difference in the plasma levels of those drugs 
extensively bound to sites I and II on albumin (warfarin and salicylic acid). They 
did find higher levels of unbound fractions of diphenhydramine, propranolol, and 
disopyramide in Chinese subjects, all are basic drugs which are more extensively 
bound to AAG. When levels of AAG were compared in the 2 groups, they were 
found to be 25% lower in the Chinese subjects. 
Feely & Grimm (1991) compared the plasma protein binding of lignocaine 
and warfarin and concentrations of AAG in Chinese and Caucasians. Their results 
were similar to that of Zhou et al There was no difference in the free fraction 
of warfarin but a significantly higher unbound fraction of lignocaine was found in 
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Chinese subjects. AAG levels were 0.66 土 0.03 in Chinese and 0.74 士 0.04 in 
the Caucasians. 
Many factors have been shown to effect AAG levels, the contraceptive pill 
(oestrogens) can markedly reduce AAG levels (Song, Merkatz, Rifkind, Gilette & 
Kappas (1970)，levels are raised in chronic renal failure (Grossman, Davis, 
Kitchell, Shand & Routledge (1982), some inflammatory diseases (Deleve & 
Piafsky，1981) and obesity (Benedek, Fiske, Griffen, Bell, Blouin & McNamera， 
1983) to name just a few. Any study which compares such levels must be strictly 
controlled to take all such factors into account. 
1,1.2 Pharmacogenetics in Asians and Caucasians 
Many studies have demonstrated an altered response in Asians to certain 
agents. Zhou et al. (1989) noted that the accepted therapeutic dose of propranolol 
was significantly lower in China than in the U.S.A. and designed a study to 
determine if there was any pharmacokinetic basis for this adjustment. They 
studied 10 Chinese and 10 Caucasian healthy, male subjects, all of whom were 
tested for the debrisoquine PM/EM phenotype, as propranolol is known to be 
affected by it (Raghuram, Koshakji, Wilkinson & Wood, 1984). One subject was 
found to be a PM of debrisoquine and was subsequently excluded. Despite this 
precaution, the results were still quite startling, the Chinese subjects were at least 
twice as sensitive to the "-blocking effects of propranolol and were also markedly 
more sensitive to its hypotensive effects. The Caucasian subjects had an AUC that 
was 77% higher than their Chinese counterparts but the plasma concentrations of 
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4-hydroxypropranol and naphthoxylactic acid (the major metabolites) were 
significantly greater in the Chinese. Propranolol clearance was also twice as high 
in the Chinese group, even after adjustment for weight. This, the investigators 
postulated, was due to increased activity of certain of the metabolic pathways. 
Zhou et al also examined the number and density of jS-receptors on lymphocyte 
membranes, but found no difference between the races. The Chinese subjects had 
a higher level of 4-hydroxypropranol but this has been previously shown to have 
little effect on the level of /^ -blockade (Raghuram et al，1984). The investigators 
could form no suitable premise which would explain the extent of the increased 
sensitivity in the Chinese subjects. However, when this study is examined in view 
of their later work (Zhou et al, 1990) it would seem that differences in the levels 
of AAG might at least partly explain the result. 
An increased sensitivity to propranolol has also been reported in Philipino 
subjects of Malay origin. Morales, Masterson, Martin and Devane (1991) 
conducted a multiple-dose study in 12 Filipino subjects with mild to moderate 
hypertension. They found that 40 mg of propranolol had the same effect in 
Filipinos as a dose of 120 mg had had in a previous study involving Caucasians. 
They proposed several possible mechanisms for this increased sensitivity. Firstly, 
an enhanced B-receptor responsiveness as had previously been reported by Zhou. 
Secondly, a stereoselective metabolism of propranolol. Propranolol is 
administered as a racemic mixture of two isomers, only one of which is 
biologically active. Morales et al propose that there may be preferential 
metabolism of the active isomer in this ethnic group, thus leading to higher 
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proportion of the biologically active metabolite in the blood. They also make the 
point that overdosing may be the cause of the disparity in the routinely prescribed 
doses between European countries and Asia. It is possible that Caucasian 
populations might also respond adequately to lower doses of propranolol if 
initiated at the start of therapy. 
Cheah and Chia (1974) examined the effects of varying doses of 
propranolol (between 30 and 100 mg) on 23 hypertensive patients of several ethnic 
groups (19 Chinese, 2 Malaysian, 1 Indian and 1 Eurasian). They found that 
propranolol was effective in lowering the blood pressure of most Asian patients, 
however it was not effective as a single agent in patients with severe hypertension. 
When used in conjunction with chlorothiazide alone or in combination with alpha 
methyl dopa, blood pressure was adequately controlled in these patients also. The 
authors rightly point out that there is a wide degree of variation in response to 
propranolol even within racial groups. Antihypertensive response to propranolol 
has been correlated with pre-treatment and post-treatment levels of plasma renin 
activity, in addition to the severity of hypertension. Propranolol is more effective 
in high-renin states and less effective in severe hypertension (diastolic blood 
pressure > 130 mmHg). Such factors should be carefully taken into account when 
discussing the possibility of an ethnic difference in the metabolism of such a drug. 
As propranolol does not induce postural hypertension in Asian patients on exercise 
or in hot weather (unlike guanethidine and alpha methyl dopa) Cheah and Chia feel 
that it is antihypertensive of choice for such patients in hotter climates. 
Yue, Svensson, Sjoqvist & Sawe (1991) made a study of the 
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pharmacokinetics of codeine in healthy Chinese and Caucasians with the 
debrisoquine EM phenotype. They found that the mean values for C^,^ in the 
Chinese were almost double that of the Caucasians and that the AUG was also 
significantly higher. This was reflected in a lower plasma clearance and a longer 
half-life in the Chinese subjects. They concluded that Chinese subjects were less 
able to metabolise codeine due to a racial inadequacy in glucuronidation. This 
difference was observed despite the fact that the Chinese and Caucasian subjects 
were actually matched according to their metabolic ratios for debrisoquine, so any 
ethnic difference could not be a consequence of variance in the incidence of the 
debrisoquine oxidative polymorphism. 
Spector, Aswini, Choudbury, Chiang, Goldberg & Ghonheim (1980) 
studied the kinetics of diphenhydramine in Caucasians and Orientals. Their data 
demonstrated a higher volume of distribution and plasma clearance in the Oriental 
subjects, but little difference in the plasma half-life. There was a higher unbound 
fraction of diphenhyramine in the plasma of the Oriental group, nearly double that 
of the Caucasians. However, the Orientals exhibited significantly less sensitivity 
to the psychomotor effects of the drug. The effect of differing diets was not taken 
into account in this study however, the same difference was found between a 
married couple, eating the same diet but in different ethnic groups. An increase 
of 1.7 times the recommended dose per kilogram for Caucasians was 
recommended to achieve equivalent effects in Chinese. However, there were only 
five subjects in each study group, and thus this result may not be very 
representative. 
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Kalow，Tang, Kadar, Endrenyi & Chan (1979) measured the levels of 
amobarbital metabolites in the urine of Chinese and Caucasians. The two main 
metabolites of amobarbital are 3-hydroxyamobarbital (formed by N-glucosidation) 
and l-(0-D-glucopyranosyl) (formed by hydroxylation). The urine from the 
Caucasian subjects contained about one third of the former product and 2 thirds 
of the latter, whilst the urine from the Chinese subjects contained equal 
proportions of both. These results could perhaps reflect a reduced ability in the 
Caucasian subjects for N-glucosidation or a increased activity of the hydroxylation 
pathway. 
Chao, Chang, Chang, Liu, Wang & Yin (1987) determined the alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) isoenzyme 
phenotypes in 71 autopsy liver specimens from Chinese patients. They found that 
the optimal pH for ethanol oxidation in 90% of the specimens was 8.5 as opposed 
to the accepted 10.5 in Caucasian patients. They also noted that 42% of the livers 
studied lacked the ALDH I isoenzyme activity, but possessed the ALDH II 
whereas the rest of the samples had both. ALDH I is needed to metabolise the 
toxic metabolite of ethanol, acetaldehyde, into its less toxic forms (Ewing, Rouse, 
Pellizari, 1974) and the increased level of this metabolite in Orientals is 
responsible for the unpleasant flushing reaction in response to ethanol which has 
become well known. A similar study in 1980 examined autopsy liver specimens 
from 40 Japanese patients and found that 21 of those lacked ALDH I the 
isoenzyme with the strongest specifity for acetaldehyde (Harada, Misawa, 
Agarwal, & Goedde (1980). 
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ACE-Inhibitors in Asians and Caucasians 
Some literature is available on the pharmacokinetics of ACE-inhibitors in 
Chinese patients. Woo and Nicholls (1990) investigated the incidence of persistent 
cough in 100 Chinese patients with heart failure or hypertension, taking either 
captopril or enalapril. These patients were compared with a control group of 
patients with cardiovascular disease but not on ACE-inhibitor therapy. They 
interviewed both groups with a common adverse-event questionnaire and found 
that the incidence of cough was much higher in those patients taking captopril or 
enalapril (56% and 46% respectively). Woo and Chan (1991) did a clinical trial 
involving 50 Chinese patients of all ages, whose blood pressure could not be 
controlled on isradipine alone. They found that the addition of lisinopril 
significantly enhanced the antihypertensive response. However, they also found 
that the incidence of dry cough in their patients (48%) was significantly higher 
than had previously been reported in trials on Caucasian subjects. Chan, Chan, 
Luk, Leung and Critchley (1993) reported similar findings. This high incidence 
of cough in Hong Kong Chinese subjects does not correlate well with studies done 
in mainland China. Liu (1993) studied the effects of captopril on over 5000 
patients who had suffered a recent myocardial infarction. She found the incidence 
of cough to be no higher than had been reported in Caucasian populations. In the 
absence of any biological evidence, differences in the way that the data has been 
obtained must become a serious consideration. It is possible that the sensitivity 
of the questionnaire used to illicit this information was greater in the studies done 
in Hong Kong than those done in European subjects. Much depends on whether 
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the patients are specifically asked whether they experienced cough. The possibity 
that there may be some sort of environmental cause for an increased incidence of 
cough in the Hong Kong population as a whole also exists (Tomlinson，Anderson, 
Chan, Chan & Critchley，1993). 
Chan, Cockram, Nicholls, Cheung and Swaminathan (1993) compared the 
efficacy ofenalapril and nifedipine in 102 hypertensive, Chinese patients with non-
insulin dependent diabetes mellitus. The patients were followed-up for a period 
of one year, having been randomly assigned to receive either enalapril 10 mg once 
daily, or modified release nifedipine 20 mg twice daily. At the end of the one 
year treatment period it was found that mean arterial pressure was similar in the 
two groups, however, overall, blood pressure was higher in the enalapril group. 
In addition, 76% of the patients on enalapril required the addition of a diuretic to 
bring their blood pressure to the desired level, whereas only 14% of those on 
nifedipine needed the addition of a diuretic. There was a higher incidence of 
withdrawal in the enalapril group, due to cough or inadequate control of blood 
pressure. The authors also found that the fall in blood pressure was slower in the 
patients taking the ACE-inhibitor than has previously been reported in elderly, 
hypertensive whites. Chan et al. could not rule out the possibility of ethnic 
differences in response. 
Athough, no direct comparisons have been made between Chinese and 
Caucasians of the pharmacokinetics of ACE-inhibitors, enough data exists in 
Chinese to make such a study of considerable importance. 
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The Renin Angiotensin System 
The various mechanisms of blood pressure (BP) control and the 
pathophysiology of hypertension are so complex that even now they are not 
entirely understood. For the purpose of this review, we will concentrate on the 
renin-angiotensin-aldosterone system (RAAS), its role in the regulation of BP and 
the inhibition of angiotensin converting enzyme and its effect on the pathogenesis 
of hypertension and vascular disease. 
The RAS is a system of hormones that influences BP in a number of ways. 
It is composed of renin, angiotensins I，II and III，and aldosterone. The system 
is activated to maintain BP in states of sodium restriction, a drop in fluid volume, 
sympathetic nervous stimulation (i.e. in response to pain or stress) or in the event 
of a drop in cardiac output. The classical pathway of the RAS system is as 
follows:- renin hydrolyses the renin substrate (of-2-globulin) in plasma at the 
leucyl-leucine bond to produce the deca-peptide angiotensin I (Al). This is further 
hydrolysed by converting enzyme with the removal of the histidyl-leucine dipeptide 
from the C-terminal end to yield the octapeptide angiotensin II (All). 
Converting 
Renin Enzyme Angiotensinases 
I \ i 
a-2-globulin — Angiotensin I — Angiotensin II — Angiotensin fragments 
A diagram of the the major components of the renin-angiotensin-aldosterone 
system is shown in Figure 1.1. There is also an alternative pathway, the renin 
substrate may be converted directly to Angiotensin III (des-Asp All), a 
heptapeptide which has only a quarter of the pressor activity of All, but is equally 
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potent in its adrenal cortical effects. This has led some to believe that it has an 
important role in the control of aldosterone secretion (Freeman, Davis, Lohmeier 
& Spielman，1977). Aldosterone is a hormone that acts on the cortical collecting 
tubules of the kidney to promote the reabsorption of sodium and water and 
increase the excretion of potassium in the renal tubules. It is an important factor 
in extracellular volume regulation. All appears to be the most important stimulus 
for aldosterone secretion by the adrenal gland (Ribeiro, Kohlmann, Sarago^a, 
Marson, & Ramos，1985). 
Renin plays a major role in the control of blood pressure and electrolyte 
metabolism. It was first isolated from the renal cortex by Tigerstedt and Bergman 
(1898). It is synthesised in the juxtaglomerular apparatus of the kidney, where it 
is found in its highest concentrations. Its secretion is stimulated by a variety of 
mechanisms. A detailed description of these mechanisms can be found in the 
articles by Davis & Freeman (1976) and Ribeiro, Kohlmann, Manoel, Saragoga, 
Marson & Ramos (1985). It is thought that the juxtaglomerular apparatus acts as 
both a baroreceptor and a chemoreceptor in regulating renin release. Its 
baroreceptor function is stimulated by a drop in perfusion pressure of the afferent 
arteriole, detected by the stretch receptors in the smooth muscle of the vessel's 
walls. Extracellular fluid depletion also reduces renal artery perfusion pressure 
and therefore stimulates renin release. The release of renin is increased with 13-
receptor stimulation and is consequently reduced by B-adrenoceptor blockers, 
despite the fact that they lower blood pressure. In contrast a-adrenergic inhibition 
stimulates renin release, independant of any hypotensive effect. Although a 
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reduction in extracellular fluid volume can affect renin release due to a 
baroreceptor effect, it is possible that the macula densa in the tubular epithelium 
of the nephrons acts as a chemoreceptor, stimulated by increased concentration of 
chloride ions in the tubular fluid. The hypersecretion of renin occurs when the 
blood pressure is low and the extracellular fluid volume is decreased. When this 
situation arises, the RAA system is the mechanism by which blood pressure is 
maintained. Extracellular fluid volume is effectively decreased by dietary salt 
restriction but in Western populations, where dietary intake of salt is quite high, 
such increases in renin release are fairly small and probably have a minor role in 
the control of blood pressure. It is only when sodium intake is drastically reduced 
that that renin levels become high enough to play an important role in BP 
regulation (see Swales, 1979). It has been suggested that the RAA system evolved 
to maintain blood pressure under conditions of relative salt deprivation, long 
before the advent of the high sodium convenience food diets of Western societies 
and is now fairly suppressed in modem man. In a healthy man consuming a diet 
containing normal amounts of sodium, the activity of plasma renin is quite low. 
Under these conditions inhibition of the pressor effects of All has little effect on 
arterial BP. However, if the individual is sodium restricted, a significant fall in 
arterial BP is more likely to occur (Ribeiro et al, 1985). The plasma half-life of 
renin is 10-15 minutes, and clearance is mainly hepatic (see Swales, 1979). 
In almost every tissue in which they have been looked for, enzymes have 
been found that form Al when they are incubated with renin substrate (Ganten, 
Hutchinson, Schelling, Ganten & Fischer，1976). Al alone has no vassopressor 
Chapter 1 - Literature Reviews 23 
activity however, and becomes relevant only once converted to All. All works 
directly on the resistance vessels and is, weight for weight, the most potent 
naturally occuring vasoconstrictor substance known (Swales, 1979). The half-life 
of All is only between 1 and 2 minutes, its excretion is mainly by enzymatic 
breakdown and uptake by the tissues. Of the angiotensin fragments, the only one 
with significant actions is AIII. 
Ideishi，Sasaguia, Ikeda & Arakawa (1990) studied the ability of tissue 
kallikreins to convert synthetic AI to All. They found that purified kallikreins 
were capable of converting AI to All at a physiological pH. This process was 
inhibited by aprotonin, (a kallikrein inhibitor) but not by captopril (an ACE-
inhibitor). The kallikrein in that study was obtained from the salivary glands of 
rats and from human urine and subsequently purified. However, a kallikrein-like 
enzyme has also been found in the vascular wall in rats (Nolly, Scicli, Scicli, 
1985). Ideishi et al. suggest that AI may be converted to All by tissue kallikrein, 
even in the prescence of ACE-inhibition which may explain why All levels rise 
on long-term treatment with ACE-inhibitors. 
Angiotensin-converting enzyme (ACE) is a metalloenzyme (containing zinc) 
which is found in many tissues throughout the body, including the lungs, kidneys, 
brain and blood vessels. It is a fairly complex molecule, which has recently been 
cloned and has more than one active site. There is apparently only one gene for 
ACE-formation but several messenger RNA molecules can be produced by 
differential splicing resulting in several different molecular forms of the enzyme 
(Sourbrier, Alhenc-Gelas, Hubert, Allegrini，John, Tregear, & Corvol，1988). An 
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examination of its primary structure reveals that it has two active sites and not just 
one, as with other proteolytic enzymes (Corvol, 1989). Although little is known 
about the second active site, it may be possible to generate a new generation of 
drugs which target the alternative site. ACE is identical to kininase II and so is 
not only instrumental in the formation of the vasoconstrictor All, but also in the 
degradation of the vasodilator bradykinin, although it is not the only enzyme 
capable of doing so (Raia, Barone, Byerly & Lacy，1990). It may have a 
dual causative role in hypertension, causing vasoconstriction by formation of All 
and also by inactivation of the bradykinin. Local formation of All may have a 
role in the control of large artery compliance, cardiac hypertrophy and coronary 
blood flow. 
1.2,1 Discovery of Inhibitors of Angiotensin Converting Enzyme 
The development of the ACE-inhibitors that we know today has been result 
of several, seemingly unrelated discoveries. It began in 1961，when a scientist by 
the name of Ferreira was using the venom of a Brazilian snake {Bothrops 
jararaca) to induce contractions in guinea pig ileum. Quite by accident, he found 
that the venom itself had strong bradykinin potentiating activity and associated this 
with a group of peptides which are present in the venom. He named his crude 
preparation bradykinin potentiating factor (BPF) (Ferreira, 1965). BPF inhibited 
plasma kininase activity, and potentiated the spasmogenic action of bradykinin 
upon isolated smooth muscle, in addition to increasing the vasodilation and 
permeability of the muscle. It had no potentiating effect on the actions of All. 
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Later Ng & Vane (1968) discovered that during its passage through the pulmonary 
vascular beds AI was converted to All by hydrolysis of the carboxyterminal amino 
acid. This conversion was very similar to that of bradykinin and later work 
showed that BPF had a very strong inhibitory effect on conversion of AI to All 
in the vasculature of the lung (Ng & Vane, 1970). Ferreira later went on to 
discover nine low molecular weight, pharmacologically active peptides of which 
the most potent was the nonapeptide, PLA-Lys-Trp-Ala-Pro or bradykinin 
potentiating factor (BPP) (Ferreira, Bartelt & Greene，1970) and to determine the 
sequence of the pentapeptide bradykinin potentiating factor (Ferreira, Greene, 
Alabaster, Bakhle & Vane, 1970). The knowledge of the structure of the peptides 
from the Bothrops venom and of the site of cleavage of BPP by ACE greatly 
helped to formulate a rational approach towards the development of ACE-
inhibitors for diagnostic purposes and for the treatment of hypertension (Ferreira, 
1985). 
1,3 ACE-Inhibiting Drugs 
Since the discoveries of Ferreira and his collegues, an explosion of research 
in this field has taken place. ACE-inhibitors are now into their third generation 
and new drugs are being developed with stunning rapidity. ACE-inhibitors lower 
BP by inhibiting the conversion of AI to All by ACE. All raises BP, not only by 
its vasoconstrictor effects, but also by sodium and water retention induced by 
aldosterone release (see Figure 1.1). As ACE not only degrades angiotensinogen 
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the kallikrein-kinin-prostaglandin system, although this has not so far been proved 
(Lancaster & Todd, 1988). ACE-inhibitors bind to the active sites on the ACE 
molecule thus effectively blocking its converting ability (Raia et al, 1990). 
Captopril was the first oral commercially available ACE-inhibitor, synthesised 
directly from a component of the Bothrops venom known as teprotide (Ondetti, 
Rubin & Cushman，1977). Teprotide itself is not useful in clinical terms as an 
ACE-inhibitor as it has a very short half-life and can only be produced in a 
parenteral form (Ondetti et al, 1977). 
It is possible to classify ACE-inhibitors according to the element in their 
structure which reacts with the zinc ion in the ACE molecule (Raia et al, 1990). 
Captopril can be classified as a dipeptide thiol as it is its sulphydryl moiety that 
reacts with the zinc ion of the ACE molecule. This particular bond is very strong 
and results in captopril having a much higher affinity for ACE than Al. However, 
the same sulphydryl moiety has been implicated in the adverse effects of captopril, 
i.e. loss of taste and skin rashes (Duchin, Singhvi & Willard, 1982) and so 
inhibitors which contain no sulphur were developed. Enalapril was the next ACE-
inhibitor to be launched. It is a prodrug which is hydrolysed in the liver to form 
enalaprilat (the active drug). Enalapril contains no sulphydryl moiety but a 
carboxyl group which reacts with the zinc ion of the ACE molecule. Although 
this bond is in fact weaker than that formed by captopril, enalaprilat has seven 
binding sites as opposed to captopril's five and this compensates for the weaker 
ligand. The result is an ACE-inhibitor which is even stronger than captopril 
(Mackaness, 1985). 
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Lisinopril is the lysine analogue of enalaprilat. The substitution of lysine 
on the enalaprilat molecule has resulted in an ACE-inhibitor which is orally active, 
and not hydrolysed in the liver. It has equal affinity for the ACE-molecule, 
making it just as potent as enalaprilat (Ulm, Hichens, & Gomez，1982). 
As so many ACE-inhibitors have been developed over the last decade that 
it is not practical to discuss the pharmacokinetic and pharmacodynamic effects of 
all of them. We shall confine ourselves to the pharmacokinetics of the two third 
generation ACE-inhibitors that were studied for this thesis, perindopril (Coversyl, 
Acetril) and cilazapril (Inhibace). 
1.3.1 Pharmacokinetics and Pharmacodynamics of Perindopril 
Perindopril was first discovered in 1980 by a chemist, M. Vincent and a 
pharmacologist, M. Laubie working for the Institut de Recherches Internationales 
Sender (I.R.I.S.). Since then it has undergone ten years of intensive research 
involving over 200 international studies in more than twenty countries (Poirier， 
1989). The chemical structures of perindopril and its metabolites and the 
pathways involved in its metabolism are shown in Figure 1.2. 
Perindopril (S9490-3) is a member of the newer, third-generation, group 
of ACE-inhibitors. It is an orally administered prodrug which is de-esterfied in 
the liver to form its active metabolite, perindoprilat (S9780) (Macfadyen, Lees & 
Reid, 1990). Perindopril itself is not pharmacologically active, however 
perindoprilat is a potent inhibitor of ACE. Apart from perindoprilat, perindopril 
forms one other metabolite, an inactive glucuronide conjugate which is renally 
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excreted. Perindoprilat itself is highly hydrophilic and has a relatively low volume 
of distribution. The plasma protein binding of perindopril is higher than that of 
perindoprilat, the majority of the former in the plasma being bound to albumin 
(Macfayden et al, 1990). Perindopril pharmacokinetics have been extensively 
studied in healthy, Caucasian volunteers. Lees and Reid (1987) studied the 
haemodynamic and oral effects of perindopril in thirty-six, normotensive, male 
volunteers. The study looked at doses of 1，2，4，8 or 16 mg of oral perindopril. 
Each dose was given for seven consecutive days to six subjects. The authors 
concluded that the appropriate dose range for perindopril appeared to be 4 to 16 
mg. The drug was well tolerated, and caused no change in the measured 
haematological and biochemical parameters. At the maximum dose of 16 mg, 
inhibition of plasma ACE was 90% at 4 hours after the dose, and 60% at 24 
hours. Inhibition of ACE-activity was dose related, as was the substantial rise in 
plasma renin-activity. Plasma renin concentrations remained elevated at 24 hours 
but the lowering of plasma aldosterone concentrations was comparatively slight 
and variable over the 24 hour period. Unlike the acute falls in both systolic and 
diastolic blood pressure of about 20-25 % at 6 hours post-administration of 4-8 mg 
perindopril observed in hypertensive patients (Lees & Reid，1987)，the falls in 
blood pressure found in the normotensive subjects (even with 16 mg perindopril) 
were small and usually not significant. Most authors do not report a significant 
increase in heart rate with ACE-inhibitors but Lees and Reid (1986 and 1987) did 
find a slight rise after seven days perindopril dosing in normotensives, but not in 
hypertensives. 
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Devissaguet, Ammoury, Devissaguet and Ferret (1990) studied the 
pharmacokinetics of perindopril in twelve healthy, normotensive volunteers (6 
male and 6 female). This study involved both an oral dose and an IV infusion of 
8 mg perindopril and also an IV infusion containing 6.1 mg of perindoprilat given 
over 2 hours. Each volunteer underwent all three of the treatment regimens. 
Plasma concentration vs. time profiles for both the prodrug and the metabolite 
were polyphasic after both routes of administration. After the oral dose, 
perindopril was absorbed rapidly and eliminated, primarily by metabolic 
conversion to perindoprilat, with approximately 20% of the dose being converted 
into the active metabolite. Renal excretion of free drug was rapid, and there was 
a prolonged terminal elimination phase, characterised by low concentrations of the 
drug. The authors admit difficulty in accurately fitting this phase, but cite a half-
life of approximately 44 hours. This study is particularly interesting as it also 
examined the fate of all the metabolites. 
Macfadyen, Lees & Reid (1992) gave intravenous infusions of 1 mg 
perindoprilat to normotensive volunteers. The subjects received randomised, 
blinded therapy with a 3 hour infusion of either the active drug or a saline 
placebo. Even at such a low dose, Macfadyen et al still saw a clear 
haemodynamic response with a significant reduction in both supine and erect 
systolic and diastolic blood pressure. No change in heart rate was seen. The 
authors advocate the use of lower doses or slow infusions of ACE-inhibitors, 
leading to a smaller free fraction of the drug and therefore, less rapid renal 
excretion. As they rightly point out, with ACE-inhibitors it is fraction of the drug 
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bound to ACE which produces the pharmacological effect, and not the free drug 
in plasma. 
The onset of circulating ACE-inhibition after oral perindopril administration 
is slower than that seen with other ACE-inhibitors. On average, it takes 
approximately 4 hours to achieve greater than 90% inhibition in normal volunteers 
(Todd & Fitton，1991). 
Waeber, Nussberger, Perret, Santoni & Bmnner (1989) examined the 
effects of repeated doses of perindopril in groups of 5 normotensive subjects. 
Daily doses of 2 to 16 mg were given daily for a period of one week. They found 
that ACE-inhibition was maximal at 4-8 hours post-dose and that ACE-activity was 
still markedly reduced at 24 hours. A significant fall in angiotensin II and 
aldosterone occured accompanied by a rise in plasma renin-activity and angiotensin 
I. However, blood pressure and heart rate were not significantly affected. 
1.3,2 The Pharmacokinetics and Pharmacodynamics of Cilazapril 
Cilazapril is a third-generation ACE-inhibitor which has been developed 
and marketed by F. Hoffmann La Roche Pharmaceuticals and Chemicals Ltd., 
Basle, Switzerland. This drug was developed with the help of computerised 
molecular graphics in an attempt to find a high potency drug with fewer adverse-
effects than captopril or enalapril (Hassall, 1985). Cilazapril is an inactive 
prodrug which is metabolised in vivo to its diacid metabolite cilazaprilat (Mulder 
& Szucs, 1989). Cilazaprilat is the only metabolite of cilazapril. The chemical 
structures of cilazapril and cilazaprilat are shown in Figure 1.3. 
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In healthy volunteers, the absorption of cilazapril and hydrolysis 
tocilazaprilat occurs rapidly and maximal concentrations of cilazaprilat are seen 
between 1 and 3 hours (Frances, Brown, Kler, d'Amore, Nussberger, Waeber & 
Brunner, 1987). The decline of cilazaprilat follows a biphasic pattern, with an 
initial rapid half-life of 1.5 hours and a prolonged terminal half-life of 
approximately 30-50 hours (Masserella, Defeo, Lin, Limjuco & Brown，1989). 
The major elimination pathway is through renal excretion (Mulder & Szucs， 
1989). 
Frances, Brown, Kler, Fasanella d'Amore, Nussberger, Waeber & Brunner 
(1987) studied twelve healthy male volunteers, divided into two groups of six, with 
each subject being given two different single doses of the drug, two weeks apart. 
The doses chosen were 1.25, 2.5，5 and 10 mg. The authors used what they term 
a "physiologically realistic" model to fit the plasma concentration time curves, 
and relate the kinetics of the drug to the dynamics of ACE-inhibition. Having 
given two doses they were also able to draw some conclusions about dose-
response. Regardless of the dose given, plasma concentrations were very low at 
24 hours, and the difference after the 1.25 mg dose and after the 10 mg dose was 
less than two-fold, leading the authors to conclude that there is only slight-dose 
dependent effect. The prolonged terminal elimination phase had a half-life of 
approximately 50 hours, however, Francis et al. admit that this phase could not 
be determined accurately and claim that no single value can be quoted for the 
terminal elimination half-life. However, they also claim that this phase is most 
relevant in relation to the pharmacodynamic effects of the drug. The inital 
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elimination phase, correlating better with the kinetics. Finally, they conclude that 
the pharmacological response to cilazapril may be relatively independent of dose. 
Fansanella d'Amore, Bussien, Nussberger, Waeber, Turini, Brunner, Kler 
& Francis (1987) gave single oral doses of 1.25, 2.5，5 and 10 mg to 14 healthy, 
male volunteers. The study was designed to investigate the pharmacodynamics of 
the drug in normotensive subjects, and from the methodology and the subjects 
used, appears to be the pharmacodynamic data from the study published by Francis 
et al (above). They concluded that in healthy volunteers, neither blood pressure 
nor heart rate were altered by any of the above doses, throughout the 72 hours 
study period. In addition, no significant difference was seen in the rate of 
recovery of ACE-activity after the four doses, which had still not returned to 
normal at 72 hours. This result also seems to imply that the pharmacodynamics 
of ACE-inhibition with cilazapril are not dose-dependant. 
Nussberger, Fansanella d'Amore, Porchet, Waeber, Brunner, Brunner, 
Kler, Brown and Francis (1987) monitored the haemodynamic effects of cilazapril 
1.25 and 5 mg in 12 normotensive male volunteers. The volunteers were divided 
into two groups of six and the dose was administered in a double-blind fashion for 
8 consecutive days. With neither the 1.25 nor the 5 mg dose of cilazapril was a 
consistent fall in blood pressure or change in heart rate observed during the 8 days 
of their administration. They report no accumulation of the active metabolite, 
despite ACE-inhibition which persisted for beyond 72 hours. 
It is worth noting that the above three studies in healthy volunteers were 
all published in the same year, with a very similar list of authors from the same 
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research centre. The number of volunteers and the study design is also quite 
similar. This raises the question that the same volunteers may have been used in 
all three studies, which could have some bearing on the results. This is of course, 
pure speculation. 
The lack of an increase in heart rate in response to a lowering of blood 
pressure through ACE-inhibition is a frequently reported reported in the literature. 
In an attempt to elucidate this phenomenon, Elliot, Ajayi & Reid (1989) designed 
a study to investigate the effect of cilazapril on indices of autonomic function in 
10 normotensive and 12 hypertensive volunteers. Normotensives received a 
single, oral dose of 5 mg and hypertensives received a single, oral dose of 20 mg. 
The authors used several tests to assess sympathetic (cold pressor test, forearm 
isometric exercises and dynamic exercise) and parasympathetic (the orthostatic 
test, apnoeic facial immersion, and heart rate variation with deep breathing) 
nervous activity and the integrity of baroreflex mechanisms (the Valsalva 
manoeuvre and orthostatic stress). A significant effect on blood pressure was not 
seen in either group, and there was no effect on heart rate. In addition, cilazapril 
failed to modify the responses to either the Valsalva manoeuvre or the orthostatic 
stress test, indicating that baroreceptor function was unaltered by ACE-inhibition 
with cilazapril. Neither was there any significant effect on the indices of 
sympathetic or parasympathetic function following ACE-inhibition. However, 
there was some evidence that parasympathetic activity was increased by cilazapril, 
an effect which the authors attribute to withdrawal of the vagolytic actions of 
angiotensin II. 
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White, McCabe, Hager and Schulman (1988) studied the effects of chronic 
monotherapy with cilazapril on blood pressure and heart rate responses in eighteen 
patients with mild to moderate hypertension. Measurements were made through 
casual recordings and also through ambulatory blood pressure monitoring. The 
casual recordings were taken in both the supine and standing positions. They 
found that cilazapril effectively lowered blood pressure and induced a modest 
decrease in heart rate. Again, the absence of a rise in heart rate is attributed to 
increased activity of the parasympathetic nervous system. Blood pressure was 
satisfactorily controlled in two thirds of the subjects studied, with only three of the 
eighteen patients requiring the addition of a diuretic. 
The effects of ACE-inhibition with cilazapril do not differ from those of 
other ACE-inhibitors in this class. However, cilazapril does appear to be more 
potent and have a longer duration of action (Kleinbloesem, van Brummelen, 





The pharmacokinetics and pharmacodynamics of two novel ACE-inhibiting 
drugs were investigated in single-dose studies performed on groups of healthy, 
normotensive Chinese and Caucasian volunteers. The recruitment of subjects, 
sample collection and subsequent treatment, and haemodynamic measurements were 
all performed by the author. The studies were of similar design and so a general 
outline of details common to both will be given in this chapter. Specific details 
peculiar to each protocol will be given in the methodology of each study (Chapter 
3，section 3.3 and Chapter 4，section 4.3). The pharmacokinetic parameters of each 
drug were to be determined from: 
• Venous blood sampling 
• Urine collections 
The pharmacodynamic effects were based on measurement of: 
• Changes in plasma renin, angiotensin I and aldosterone concentrations 
參 Levels of ACE-activity and extent of ACE-inhibition 
• Systolic blood pressure, diastolic blood pressure and heart rate 
• Transthoracic bioimpedance, allowing calculation of heart rate, stroke index, 
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cardiac index, ventricular ejection time and thoracic fluid index. 
All measurements were taken by qualified nurses under the supervision of a 
physician. The studies were performed in the Clinical Pharmacology Studies Unit 
(CPSU) of the Department of Clinical Pharmacology, Chinese University of Hong 
Kong, Prince of Wales Hospital, Shatin. 
2 . 2 SUBJECTS 
Volunteers were recruited from the staff of the hospital, including medical 
students, with the exception of some of the Caucasian subjects who were recruited 
through notices placed in the British Council Building, Causeway Bay, Hong Kong. 
All subjects were healthy normotensive volunteers and this was established 
by a thorough medical examination prior to their acceptance into the trial. The 
investigations performed varied slightly according to the protocols (see Chapters 3 
and 4 for details) but all subjects underwent standard clinical biochemical and 
haematological investigations, a full medical examination, an electrocardiogram 
(ECG) and the mean of three sitting blood pressure measurments. Urine was tested 
for protein, glucose and blood. 
A high incidence of J5-thalassaemia minor was found in our Chinese subjects. 
As this syndrome is very common in Southern Chinese (Chan, Chan, Chan, Lau, 
Ghosh, Chan, Todd, 1991), we decided to include subjects with this condition in 
the study. Only subjects of direct Chinese (Hong Kong/Mainland China) or 
Caucasian (Europe/U.S.A.) descent were accepted as suitable for the trials. 
Permission was obtained from the Faculty of Medicine of the Chinese 
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University Clinical Research Ethics Committee prior to the commencement of both 
studies. All the volunteers gave their written informed consent before being 
included in any research. Each subject was given a full verbal explanation of the 
procedures and any possible risks involved and given the opportunity to question 
a member of the Department's medical staff. An example of the informed consent 
form which was used for both perindopril and the cilazapril trials can be found in 
Appendix Al . An example of a subject information sheet is shown in Appendix 
A2. 
2.3 SAMPLE COLLECTION 
2.3.1 Blood samples 
All blood samples were venous and usually obtained via a 21 gauge 
Angiocath catheter in an antecubital vein. Blood was collected into standard 
heparinised tubes for the measurement of drug concentrations. Blood for hormones 
was collected into sodium EDTA tubes. Following collection, the samples were 
immediately placed in crushed ice and centrifuged within 15 minutes of collection. 
All samples were centrifuged at 4°C for 10 minutes at 3000 rpm using a Beckman 
AccuSpin FR refrigerated centrifuge. Following centrifugation, the plasma was 
separated and stored at -20。C until analysis. Plasma for hormone determinations 
was stored at -40。C. 
2.3.2 Urine samples 
Urine was collected in the same manner for each trial, although the 
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collection medium varied. In all cases subjects were instructed to empty their 
bladders into a receptacle 10 minutes before taking the drug. A 10 ml aliquot of 
this initial sample was then saved as a 0 hour sample, and the rest discarded. The 
subject then commenced timed urine collections, at the end of each time period 
emptying his bladder into the collection bottle for that period before receiving 
another one. After mixing to ensure homogeneity, urine from each collection was 
measured in glass measuring columns, accurate to within 10 mis for each 100 ml. 
Small urine volumes (i.e. less than 50 mis) were measured in a column accurate to 
within 2 ml. 
2.4 BLOOD PRESSURE AND HEART RATE MEASUREMENTS 
Blood pressure and heart rate were measured using a Dinamap Accutor 1 
automatic sphygmomanometer, fitted with the standard adult cuff. This machine 
was also used to measure blood pressure during the non-invasive haemodynamic 
monitoring sessions. The Dinamap Accutor is a microchip controlled device 
designed to non-invasively and automatically measure systolic and diastolic 
pressure, mean arterial pressure and pulse rate. The built-in timer can be set to 
start recording at various intervals, from 1 minute to every hour. The results are 
displayed on the front panel and can also be printed out. 
2 . 5 MEASUREMENT OF TRANSOTHORACIC ELECTRICAL BIOIMPEDANCE 
Measurement of transthoracic electrical bioimpedance (TEB) was performed 
using the BoMed NCCOM3-R7 non-invasive haemodynamic monitor connected to 
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an IBM compatable computer for data storage and subsequent spreadsheet analysis. 
This system enabled us to measure heart rate, stroke index, cardiac index, 
ventricular ejection time and thoracic fluid index as described below. 
2,5 A Background 
Cardiac output in man is conventionally measured by CO2 rebreathing, dye 
or thermodilution techniques, based on the Pick equation. Another modem 
approach is to use dual beam Doppler ultrasound. However, all these techniques 
were impractical to use in conjunction with our pharmacokinetic studies, e.g. 
involving the insertion of pulmonary artery catheters or highly skilled ultrasound 
techniques. In addition they do not give a continuous measurement of stroke 
volume and cardiac output on a beat-to-beat basis. Thoracic electrical bioimpedance 
cardiography, on the other hand, was developed in the NASA Space Programme 
for the unobtrusive continuous monitoring of the stroke volume of astronauts via 
body surface electrodes. 
Changes in thoracic impedance in relation to the cardiac cycle had already 
been documented by Atzler and Lehmann in 1932. By 1939，Nyboer had developed 
a model for utilising the impedance changes in the thorax, assuming that it was a 
cylindrical segment (see Nyboer, 1959). The NASA research, lead by Kubicek, 
then resulted in the empirical derivation of the formula for stroke volume which 
was to be later modified by Sramek (see below). 
B. Bo Sramek set up BoMED Medical Manufacturing Ltd (P.O. Box 4673, 
Irvine, California, 92718, U.S.A.), the company that developed the electrical 
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bioimpedance device, the NCCOM3-R7, used in our studies. It estimates changes 
in blood flow in the aorta by the measurement of changes in the electrical 
conductivity of the thoracic body segment. The resistance of this segment is 
measured by the flow of a high frequency, low magnitude constant alternating 
current. The measurement current's high frequency, and low magnitude make the 
procedure safe and imperceivable to the subject. The thoracic segment begins at 
the level of the root of the neck and ends at the diaphram. Thus the impedance of 
the thorax is sensed by pairs of electrodes placed at these two positions making the 
intervening segment a transducer or volume conducter. Within the latter, the 
plasma is by far the most electrically conductive substance while the alveolar air 
can be considered non-conductive. In order to provide a current flow through this 
thoracic transducer in a direction parallel with the spine, two additional pairs of 
current injecting electrodes are placed outside the sensing area i.e. 5 cm above the 
root of the neck and 5 cm below the diaphram at the level of the xiphistemum (see 
Figure 2.1). A 2.5 mA current is injected at a high frequency of 70 khz giving a 
potential across the thoracic segment of about 30 mv and this current will seek the 
most conductive pathway (which will be through the plasma in the aorta and 
superior and inferior vena cava). From the sensing electrodes the impedance (Z) 
of the thoracic segment is determined and used in the algorithm derived by 
Sramek's group. 
In the early animal studies, Kubicek's team had recorded the first derivative 
of the change in thoracic impedance with the cardiac cycle (dZ/dt) and showed that 
the peak dZ/dt was related in both timing and magnitude to the peak blood flow in 
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the aorta. This relationship was confirmed in man and interestingly, the blood 
content of the ventricle did not appear to have any important effect upon the 
impedance signal (Kubicek et al” 1968). The work of Kubicek's team had led to 
the Minnesota Impediance Cardiograph. The Bomed NCCOM3-R7 subsequently 
developed by Sramek has a number of improvements. The Minnesota Impedance 
Cardiograph's band electrodes being replaced with the above mentioned pairs of 
standard ECG electrodes which improved subject acceptability. The internal 
computer in the NCCOM3-R7 uses the latest algorithm based on the Bemstein-
Sramek equation resulting in the on-line output of stroke volume and other 
haemodynamic parameters. The Bemstein-Sramek formula for stroke volume is as 
follows: 
SV = VEPT X VET X (dZ/dt)^^ /TFI 
where SV is stroke volume, VEPT is the volume of electrically participating tissue, 
VET is the ventricular ejection time and TFI is the thoracic fluid index. The TFI 
is actually the basal impedance value (i.e. Z。) nd the major contributor to changes 
in TFI is the blood content of the capacitance vessels. 
VEPT is the physical volume of electrically participating tissue (i.e. tissue 
within the measured segment through which the current has to flow between 
injecting electrodes). In theoretical cylindrical segments, VEPT is the volume of 
the cylinder reduced by the volume of nonconductive components (bone and fat). 
In the short-term, in any one individual this is a constant and related to the 
observed-to-ideal weight ratio and height. 
The parameters analysed to evaluate the effects of ACE-inhibition in Chinese 
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and Caucasians were as follows: 
Parameters such as Heart Rate (HR), Stroke Index (SI), Cardiac Index (CI), 
Thoracic Fluid Index (TFI) and Ventricular Ejection Time (VET) were calculated 
directly by the NCCOM3-R7 using its internal algorithms and simultaneously 
recorded on the computer using software developed for the purpose by Dr Albert 
Lee of the Chinese University's Faculty of Medicine's Computing Unit. 
Stroke Index (SI) was stroke volume adjusted for body surface area calculated from 
height and weight. Cardiac Index (CI) was cardiac output adjusted for body surface 
area calculated from height and weight. Systemic vascular resistance index (SVRI) 
was calculated from the mean blood pressure and cardiac index values assuming the 
contribution of central venous pressure in our healthy subjects to be negligible. 
2 . 5 . 2 Practical Details 
Prior to the attachment of the electrodes the patients skin was prepared by 
first rubbing the site with mildly abrasive paper to remove dead cells. The area 
was then wiped with an alcohol swab to remove debris and allowed to dry before 
the electrode was attached. This ensured maximal contact of the electrode with the 
skin. The initial choice of electrode was made by repeated monitoring sessions 
conducted on the author and colleagues using "Red Dot" pregelled Ag/AgCl adult 
electrodes (3M Medical-Surgical Division, St. Paul, MN, U.S.A.) and the more 
expensive "Conmed" pre-gelled Ag/AgCl adult electrodes (Consolidated Medical 
Equipment Inc., 310 Broad Street, Utica, New York 13501，U.S.A.). It was found 
that the Conmed electrodes gave better contact with the skin whilst the the subject 
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was moving, leading to fewer error messages from the Bomed and less loss of data. 
As a result the Conmed electrodes were used for all monitoring sessions. The 
positioning of the electrodes is shown in Figure 2.1. 
Subjects rested in the supine postition for a period of five minutes prior to 
monitoring. Every attempt was made to keep the environment as quite as possible 
and the subjects were asked not to speak once the monitoring session had begun. 
Several isometeric exercises were employed in the monitoring protocols. 
The Valsalva manouevre was performed by attaching a mouth piece on the end of 
a length of plastic tubing to a standard mercury sphygmomanometer, in place of the 
cuff. The subject was then requested to take a deep breath and exhale into the tube 
until the mercury reached the 40 mm mark, and then maintain that level for a 
period of 15 seconds. The handgrip was measured by first establishing the 
maximum handgrip of the individual using a grip dynamometer (0-100 kg W; Takei 
Kiki Kogyo, Japan). This allowed us to establish maximum handgrip in strong 
males but proved unsuitable for maintaining the grip as after the initial pressure, the 
needle remained at its maximum level and had to be manually reset to zero. This 
meant that it was possible to slacken the grip without affecting the reading. We 
therefore used this device simply as a guide to maximum strength. We then devised 
5 a system that would be more sensitive to fluctuations in grip, a rubber bulb attached 
to a portable sphygmomanometer in place of the cuff. However, this meant that we 
must approximate the reading in Kg to mmHg. This was achieved by testing 15 
female volunteers, who were not strong enough to push the needle to the maximum 
on a portable sphygmomanometer, and measuring their maximum grip in Kg and 
also in mmHg. The volunteers repeated the experiment three times and the mean 
of the three reading for each instrument was taken. The following calculation was 
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then performed for all 15 subjects: 
Mean value in mmHg = Conversion factor 
Mean value in Kg 
Finally，the mean of all the conversion factors for all twenty subjects was taken. 
Table 2.1 gives the mean values obtained in mmHg and Kg for each subject and 
Figure 2.1 shows correlation between the results in mmHg and Kg. From Table 
2.1 it can be seen that there is approximately 13.6 mmHg to 1 Kg. For ease we 
tried a conversion factor of both 13 and 14, the results of which can be seen plotted 
in Figure 2.2. Both lie equally close to the regression line and so 13 mmHg was 
chosen. The rationale being that it is better to slightly underestimate the handgrip 
than to over-estimate it (most subjects found it very hard to maintain 30% of their 
maximum handgrip for the prescribed time). When a subject's maximum handgrip 
was measured using the grip dynamometer the result in Kg was multiplied by 13 
to give a value in mmHg. The study subjects were asked to maintain 30% of their 
maximum hand grip (in mmHg) for a period of two minutes. Deep breathing was 
also included in the protocol for the cilazapril study, the investigator instructed the 
subject when to breath in and out at a rate of six breaths a minute, for a period of 
two minutes. 
2.6 DATA ANALYSIS 
2,6,1. Analysis of Pharmacokinetic Parameters 
All of the pharmacokinetic data was analysed using the SIPHAR 
pharmacokinetic modeling programme (Simed, Centre d'Etudes et de Recherches 
en Statistiques et Informatique Medicales, Cedex, France). This is a highly 
interactive programme which provides a "peeling" function to initially estimate the 
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Table 2.1： Mean values of 3 attempts at maximum handgrip, using the grip 
dynamometer in Kg and the mercury sphymomanometer in mmHg, for 15 female 
volunteers. 
Sttbj^ mmHg Kg mmHg/% Kgxl4 Kgxl^ 
1 300 26.0 11.5 364 338 
2 340 27.0 12.6 378 351 
3 296 21.0 14.1 294 273 
4 310 26.0 11.9 364 338 
5 430 29.5 14.6 413 384 
6 300 22.0 13.6 308 286 
7 430 27.5 15.6 385 358 
8 240 21.0 11.4 294 273 
9 300 22.0 13.6 308 286 
10 270 18.0 15.0 252 234 
11 380 22.5 16.9 315 293 
12 310 24.5 12.7 343 319 
13 270 19.5 13.9 273 254 
14 320 27.0 11.9 378 351 
1 5 310 21.0 14.8 294 273 
Mean: 320 23.6 13.6 331 307 
SD: 55.0 3.40 1.60 47.4 44.0 
SEM: 14.0 0.90 0.40 12.2 11.4 
。 
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风职re 2.2: Correlation between the maximum handgrip in mmHg and the 
maximum handgrip in kg for 15 female volunteers. The two possible conversion 
factors are plotted on either side of the regression line. 
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parameters but also permits the use of user defined parameters. "Peeling" (also 
known as "feathering or the "method of residuals") describes the process of 
estimating the parameters necessary to fit an exponential curve to the experimental 
concentrations of a drug which requires a multicompartmental model for analysis. 
This involves viewing the plasma concentration v .^ time curve on a semi-
logarithmic scale so that the best fit of the line to each phase can be determined. 
After estimating how many points should lie on each phase, a simple least-squared 
regression can be performed which gives the slope (exponential) and the Y intercept 
(coefficient) of each phase. These are the exponentials and coefficients that can be 
seen in the SIPHAR printout (see Figure 2.4). A line can then be drawn through 
the points in question using the equation of the straight line: 
Y = mx + C 
Where Y is equal to the estimated plasma concentration, m is the slope, x is sample 
time and C is the constant (Y intercept). SIPHAR's initial peeling function simply 
performs the regression and then uses the estimated parameters to start iterations 
on the curve. However, it was not always possible to get the best possible fit of 
the data when the initial parameters estimated by SIPHAR were used. When an 
unsatisfactory result was obtained, the parameters were estimated by hand and then 
put into the programme. If this still did not improve the fit, the curve was 
examined and the parameters adjusted to make the curve more or less steep in 
certain places. In order to make this process easier, a programme was developed, 
using the Quattro Pro software. The initial coefficient (y-axis intercept) and it's 
exponential ("slope") were entered into the spreadsheet, one of these parameters 
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was adjusted (usually the slope). The change was then automatically calculated as 
a percentage and the other parameter altered proportionally. These new figures, 
which had both been increased or decreased by the same percentage were then put 
through the SIPHAR programme. This process was repeated until the curve was 
visually satisfactory, which allowed a substantial improvement of some of the fitted 
curves (see Figure 2.3 & Table 2.2). 
The reliability of the SIPHAR programme was tested prior to commencing 
analysis by taking the parameters that it generated for one subject and using them 
to simulate an "ideal data set" from the equation used to fit the data (see below). 
The ideal data was then entered into SIPHAR and an identical analysis was 
performed. The results were very similar. Table 2.3 shows the simulated data and 
the initial parameters that were used to generate it. Figure 2.4 is the report 
generated by the SIPHAR programme when the data was analysed. 
Both the ACE-inhibitors and their active metabolites were fitted to a 
triexponential model using the following equation, which does not force the fitted 
curve through the origin: 
Y = -Ce-ct + Ae-at + g^ -Bt 
Where Y equals the plasma concentration of perindopril at time t，and C and A and 
B are the coefficients of the absorption phase, alpha phase and beta phase 
respectively. The exponentials c, a, and J3 are the slopes of the respective phases 
(as the equation is in natural log). The model was fitted to the data using the 
extended least squares algorithm. The minimisation algorithm used was Powell. 
The pharmacokinetic parameters for both trials were obtained in the manner 
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described below: 
The ti/2 for each exponential phase was calculated from the slope of the 
regression line (X) using the standard equation: 
tVi = 0.693/X 
The peak plasma concentration (C„J and time to reach the peak (t„J were 
taken directly from the individual data. 
The area under the plasma concentration time curve (AUG) were calculated 
from 0 to the last measurable concentration (AUQ) using the trapezoidal rule and 
extrapolated to infinity (AUC J using the slope of the terminal phase. 
Mean residence time (MRT) can be defined as the total residence time for 
all the drug molecules in the body divided by the total number of drug molecules. 
SIPHAR calculates this parameter in the following way: 
E Coefficientj/Exponentialj^ 
(if there is no lag time) where i corresponds to the absorption, alpha and beta 
phases. 
Clearance (CL) was calculated as: 
CL/F = Dose/AUC«, 
where F is the fraction of the dose absorbed. 
Volume of distribution (Vj) for the beta phase was calculated as: 
Vd/F = CL/t,邱(F < 1). 
The criteria used to assess the reliability of the association between the 
calculated points and the observed points were the residuals, the Akaike, Leonard 
and Schwarz values and the coefficient of variation calculated for each parameter. 
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^gure 2.3: a) A plot of the the best fit of the estimated plasma concentration vs. 
time curve as calculated by SIPHAR. b) A plot of the best fit of the estimated 
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Table 2.2: The actual plasma concentrations compared with the estimated 
concentrations from the best fit from SIPHAR (A) and the estimated concentration 
after alteration of the parameters (B). The difference between the observed 
concentration and the estimated concentration (residuals) are also shown. 
a) 
Time Cone. A B Residuals A Residuals B 
0 0 -89.7 -298 89.7 298 
0.5 0.35 0.350 0.350 0.000 0.000 
1.0 7.37 25.6 38.9 -18.3 -31.6 
1.5 39.1 30.0 38.2 ^ 0.927 
2 29.5 28.1 32.5 -3.02 
3 28.4 ^ ^ 7.33 5.99 
4 19.4 15^ ^ 4.24 3.97 
6 6.91 7 M -0.970 -0.582 
8 4.82 ^ ^ 0.566 0.991 
24 0.66 0.637 0.636 0.023 0.024 
48 0.48 0.507 0.509 -0.027 -0.029 
72 0.42 0.412 0.411 0.008 0.009 
b) 
Parameter A B CV A CV B 
I I (%) (%) 
B 0.768 0.780 5.70 7.10 
B 0.009 0.009 11.6 14.4 
A 59.1 69.6 21.6 21.8 
(X 0.352 0.389 10.1 9.30 
-C 150 369 3.60 5.80 
c 2.19 3.71 17.9 8.10 
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Table 2.3: a) The parameters calculated by SIPHAR for one subject after a 
weight-adjusted dose of perindopril and used to create a simulated data set for 
penndopnl concentration b). Cone. A = the simulated data set and Cone. B = the 
fitted line calculated by SIPHAR. 
a) 
Parameter Initial Values After Refitting 
B 9.35 9.36 
B 0.195 0.195 
A 530 542 
a 1.12 1.13 
-C 754 794 
C im 1.87 
b) 
Time Cone. A Cone. B 
m (ftg n <fig a 
0.5 ^ 21.8 
1.0 ^ 66.7 
1.5 ^ 60.8 
2.0 46.4 44.8 
3.0 21.2 20.6 
4.0 9.70 
6.0 ^ 3.50 
8.0 ^ 2.00 
12.0 ^ 0.900 
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Figure 2.4: The report generated by SIPHAR after fitting the simulated data set 
and the log-linear plot of the fitted curve superimposed on the data points. 
• . • 
Parameters Half-life 
(Hours ) 
coef( 1 ) (Ig/l ) ： 9.3552 
Exp ( 1 } (l/Houre ) ： 0.1954 3.5482 
Coef( 2 ) (ig/l ) ： 541.9700 
Exp ( 2 ) (1/Hours ) : 1.1312 0.6128 
- C o e f ( 3 ) (tg/l ) ： 749.1554 
Exp ( 3 ) (l/Hours ) ： 1.8668 0.3713 
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As several different equations could be used to fit the same data set it was important 
to have stringent criteria for the acceptance of the fit. The Akaike value is derived 
from the following equation: 
A= -log likelihood + P 
where the log-likelihood value is equal to the sum of squared differences between 
computed and observed points in the hypothesis of a normal distribution and P is 
the number of estimated parameters (Simed, 1991; p 73). The Akaike value, also 
known as the Akaike information criterion (AIC), allows comparisons of formulas 
with differing numbers of parameters. The AIC value has no unit and is used only 
to compare different models within a group, all with the same numbers of 
observations (Akaike, 1976). 
Schwarz modified the Akaike，s equation to give the highest probability of 
a good fit. His equation takes account of the number of data points (N), rather than 
the number of parameters: 
L= -log likelihood - Vi log N (Simed, 1991; p 74). 
Leonard has proposed yet another more complex approach which is based 
on the number of parameters for the fit: 
L = -log likelihood - Vi P log + log H 
where P is the number of estimated parameters and H is defined as the determinant 
of the second partial derivative matrix (Simed, 1991; p 74). 
The coefficient of variation (CV) for each parameter was based on the 
equation: 
CV% = SD X 100 
P 
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where SD is the standard deviation and P the parameter value. The parameter 
standard deviation is computed using the the variance-covariance matrix; the CV 
gives an indication of the accuracy of that estimate. If the CV is greater than 20-
30%, the error can be considered too large to be acceptable. In such cases the 
model and/or the computed algorithm must be revised (Simed, 1991; p 73). 
2.6,2 Analysis of Pharmacodynamic Parameters 
The serum values of ACE-inhibition were calculated assuming that the serum 
ACE-activity before the first dose represented 0% inhibition. The percentage of 
inhibition of ACE was calculated at each time point from the ratio: 
ACE-activitv before treatment - ACE-activity at time (t) x 100 
Activity before treatment 
The maximum percentage inhibition the time taken to reach this 
maximum ( t l ^ and the percentage of ACE-inhibition at 24 hours post-dose (I24) 
were obtained from the individual graphs of percentage inhibition of ACE (%) 
versus time. 
The areas under the curve (AUCI) of percentage of ACE-inhibition v .^ time 
were calculated using the trapezoidal method between time 0 and the last 
experimental point measured. 
Aldosterone time-course and plasma renin activity time-course were 
evaluated for each patient from 0 hour to the last experimental point measured. 
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Analysis of Non-Invasive Haemodynamic Monitoring Data 
Analysis of the data generated by the NCCOM3-R7 posed a number of 
problems. Firstly, large amounts of data were generated from each monitoring 
session (each data file contained around 2000 lines of data). Secondly, although the 
data was stored in an IBM Dos compatible ASCII file, it contained no labelling of 
any kind, with the exception of time. However, a system was devised whereby the 
file was imported into a spreadsheet programme for analysis (Quattro Pro, Version 
3). A detailed record was kept of all monitoring sessions which included the 
precise time of any position change or isometric exercises. These records were 
used to divide the data into the relevant sections. The sections were then labelled 
and averaged and the result transferred to a seperate spreadsheet for each subject. 
When this had been done for every subject, the results were combined in another 
spreadsheet for analysis. In order to expedite the process, a large number of 
"macros" were written. A macro is a series of keystrokes or commands which can 
be recorded and named. When the macro is recalled, an identical sequence of 
keystrokes is replayed. One macro could be used to search out and average the 
relevant data and another to transfer the calculated means to the correct place in a 
new spreadsheet. In addition, spreadsheets were used as "forms". Blank 
spreadsheets were created with all the labels and formulas which would be the same 
for each subject. All mathematical calculations were entered as formulas which 
pertained to specific (empty) cells. When data was transferred into these 
spreadsheets, the values were automatically calculated. The spreadsheet was then 
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data. The raw data itself was always imported into a spreadsheet containing text 
labels for all of the parameters, the data was then placed underneath (see Figure 
2.5). This system meant that the labelling and formating of spreadsheets need only 
be done for one subject. Due to time limitations and an initial analysis not 
revealing any significant findings, certain parameters generated by the NCC0M3-
R7 were ignored for the purpose of this thesis. 
The calculations involved for the analysis of the data were comparatively 
simple. The data for certain time periods were meaned in each individual. Due the 
variability in such haemodynamic data, the percentage change in some parameters 
was often calculated. Data after the Valsalva manoeuvre is expressed as the 
Valsalva ratio which is calculated as the mean heart rate in the minute following the 
manoeuvre (which reflects the bradycardia after release; Ewing & Clarke, 1982) 
divided by the peak heart rate during the manouevre. During sustained handgrip, 
a sharp rise in blood pressure occurs and this change was evaluated by taking the 
maximum and minumum values during the handgrip and calculating the percentage 
change in blood pressure from the minute prior to the stress. The heart rate 
response to standing is mediated by the vagus nerve which induces a rapid increase 
in heart rate, maximal around the 15th beat in the upright position, followed by a 
bradycardia occuring around the 30th beat. Ewing & Clarke (1982) recommend 
assessing this change by the 30:15 ratio, which is the lowest heart rate occuring 
around 30th beat divided by the peak heart rate occuring around the 15th beat. 
These values were obtained by graphing the heart rate data obtained in the minute 
after standing and visually determining the peak and trough values, which do not 
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always occur at exactly the 15th and 30th beats. 
2.7 STATISTICAL ANALYSIS 
As the number of subjects in each group was never greater than twelve, it 
was meaningless to make any assumptions about the distribution or variance of the 
population prior to analysis. For these reasons both parametric and non-parametric 
tests were performed on all data, with the assumption that these tests should concur 
unless significance was borderline or the distribution highly abnormal. 
The issue of outlying values is difficult to address when dealing with small 
study populations. It was felt that the groups studied were not big enough to prove 
a normal distribution, and so it was not possible to say that certain values lay 
outside the normal distribution. For this reason, all outlying values were included 
in the analysis unless they were associated with obvious experimental error. Any 
such exclusions will be discussed in the text. 
Comparisons made on unpaired data, i.e. between the racial groups, were 
made with the Student Unpaired t-Test and its non-parametric equivalent, the Mann-
Whitney U test. Intra-group comparisons were made with the paired Student t-Test 
and the non-parametric equivalent Wilcoxon Signed Rank Test. The only 
exceptions to these rules, were with t^^ and tl腿，as these values are not suitable 
for parametric analysis. In addition, the values for plasma renin-activity and 
aldosterone concentration after cilazapril administration contained many values 
outside the range of the assay, and so a parametric test was not appropriate. In 
addition a one-way analysis of variance with repeated measures (repeated measures 
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ANOVA) was performed on the data for blood pressure and heart rate at every time 
point. 
Significant results were corrected for multiple comparisons using the Tukey-
Kramer Procedure which is described by Ludbrook (1991). This test is sometimes 
called the "honestly significant difference (HSD) or the "wholly significant 
difference" (WSD). The test involves modifying the test statistic t to q，by the 
formula: 
q，= V2(t) 
The critical values for q，were then found in a table of the Studentised Extreme 
Range (Geigy Scientific Tables, 1982, p58). This procedure was preferred to the 
Bonferroni Procedure which adjusts for the number of comparisons in the following 
way: 
p，= 0.05/k 
Where p，is the adjusted significance value and k is the number of comparisons 
made. The above formula assumes that 0.05 is the chosen significance level, but 
of course, the principle is the same for all levels of significance. However, the 
Bonferroni Procedure tends to overprotect the null-hypothesis when a large number 
of comparisons are made, leading to an increased risk of Type II error (falsely 
rejecting a significant result). On the other hand, when a non-parametric statistical 
method was used, and a t value was not generated, the Bonferroni correction was 
used, i.e. with the comparisons of aldosterone concentrations after cilazapril 
administration. 
More than one statistical package was used to analysis the data. The 
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pharmacokinetic parameters generated by SIPHAR were transferred to the statistical 
programme provided with that software (S-Stat). This programme allows the 
simultaneous performance of both parametric and non-parametric statistical tests. 
ACE-activity, plasma renin-activity, angiotensin I and aldosterone concentrations 
were also imported into S-Stat for analysis. A repeated measures ANOVA is not 
available with the S-Stat package and so the SigmaStat statistical software was used 
(2591 Kemer Blvd.,San Rafael, CA 94901, U.S.A.). 
Results are expressed as the mean 士 the standard error of the mean (SEM) 
or the mean 士 the standard deviation (SD) where that was more appropriate. Non-
parametric data is presented as the median plus the range. The level of statistical 
significance chosen for all subjects was p <0.05. 
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CMjpMr 3 
The Perindopril Study 
3.1 INTRODUCTION 
Perindopril was developed in Europe and as a result, virtually all of the 
knowledge of its pharmacokinetics and pharmacodynamic effects was gained in 
Caucasian volunteers. Although several therapeutic trials have been conducted in 
China (Liu, 1993), a direct comparison of its pharmacokinetics in Chinese and 
Caucasians living in the same environment and, at least on study days, eating the 
same diet has not been performed. In view of the growing popularity of 
angiotensin-converting enzyme inhibitors in the treatment of hypertension and the 
increasing evidence regarding ethnic differences in the incidence of their side-
effects, such as cough, it is important to establish if there are any differences in 
their pharmacokinetics and pharmacodynamics. This is particularly important with 
regard to Chinese as they form such a large percentage of the global population. 
3.1.1 Aims 
The aim of the trial was to study the pharmacokinetics and 
pharmacodynamics of perindopril and its active metabolite perindoprilat in healthy, 
normotensive Chinese and Caucasian volunteers. The kinetics would be studied on 
two occasions after a 4 mg, and a 4 mg/70 kg weight adjusted oral dose. 
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The plasma pharmacodynamics would be studied on both occasions by 
measurement ACE-activity, ACE-inhibition, plasma renin-activity, angtiotensin I 
and aldosterone concentrations. Assessment of cardiovascular function was made 
by measurement of heart rate and blood pressure. Additional information on 
inotropic and chronotropic responses was gained with the use of the NCCOM3-R7 
non-invasive haemodynamic monitor. This allowed beat-to-beat meausurements of 
stroke volume and cardiac output and a number of other parameters. Systemic 
vascular resistance was subsequently calculated. 
The results would then be directly compared for significant differences, 
having been obtained in the same controlled environment for each individual. 
3.2 METHODOLOGY 
3.2.1 Inclusion Criteria 
• Male or female, but with the same ratio in each group. If female, not of 
child bearing potential e.g. post-menopause, post-hysterectomy, I.U.D. in 
situ or taking an oral contraceptive 
• Aged 18 - 50 yrs 
• Body weight not deviating more than 20% from normal weight 
(Metropolitan Life Table, not applicable in Chinese populations) 
眷 Non-smokers or smokers of less than 5 cigarettes per day 
• Normotensive (supine BP ^ 140/90 mmHg) 
參 Giving their written informed consent 
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Non-Inclusion Criteria 
• Volunteers who do not conform to the inclusion criteria 
• Subjects who present a significant history of cardiovascular, hepatic, renal, 
respiratory, digestive, endocrine, mental or metabolic disease 
• Drug hypersensibility 
• Alcohol or drug abuse/addiction 
• Subjects who have participated in any clinical trial within the last 3 months 
• Ingestion in the previous 3 months of the following drugs: anticonvulsants 
(e.g. phenobarbital, phenytoin); neuroleptics; anxiolytic drugs; narcotics; 
anaesthetics; rifampicin; cimetidine; erythromycin; troleandomycin; 
allopurinol; gastric antacids; or any drug which can modify absorption, 
distribution, metabolism or excretion of another drug. 
• Not on any concurrent medication, with the exception of an oral 
contraceptive 
3.2.3 Study Design 
The studied was performed in accordance with the protocol and the revised 
Declaration of Helsinki (1983) governing experimentation with human volunteers. 
Subjects gave their written informed consent before inclusion in the trial (Appendix 
A l , informed consent form and subject information sheet) and approval was 
obtained from the University Ethical Committee. 
We studied 12 Chinese and 10 Caucasian, healthy, normotensive volunteers. 
The male to female ratio was 1:1 in the Chinese group but due to recruiting 
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difficulties, there were 6 males and 4 females in the Caucasian sample. The 
comparative height, weight and age of the two groups are shown in Table 3.1. 
raWe 3.1: Characteristics of the study population and the mean weight adjusted 
dose (WAD) for each racial group (mean 士 SD plus range). 
Race n M:F Age (yr) Weight (kg) Height (cm) WAD (mg) 
Chinese 12 6:6 25 土 5.4 59 士 9.2 165 土 8.8 3.4 士 0.2 
(20 -41) (48 - 75) (155 - 182) (2.5 -4) 
Caucasians 10 6:4 30 土 2.3 72 土 12 175 土 9.5 4.0 士 0.3 
(20 - 40) (52 - 94) (162 - 192) (3 -一5.5) 
Prior to selection all volunteers underwent a thorough medical examination. 
This included a complete medical history, an electrocardiogram (ECG), blood 
pressure (BP) and heart rate (HR) measurement both supine and standing, and a 
clinical examination. Blood was taken for a variety of biochemical and 
haematological investigations: 
• Haematology: haemoglobin, haematocrit, red and white blood cell counts, 
including differential white cell count and platelet count 
• Biochemistry: sodium, potassium, chloride, bicarbonate, protein, urea， 
creatinine, ALAT, gamma GT, total bilirubin, glucose, cholesterol and 
triglycerides 
• 24 hour urine analysis: sodium, potassium, chloride，urea, creatinine, test 
for presence of glucose and protein with quantification if necessary 
Those subjects who met the inclusion criteria returned to start the study 
within fourteen days. 
A single oral dose of perindopril was administered with 100 ml of water. 
On Day 1 the subject received a 4 mg capsule whilst on Day 14, a 4 mg/70 kg 
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weight-adjusted dose was given through a combination of small dosage capsules 
(accurate to within 0.5 mg). After the dose had been given, subjects were 
required to rest in the supine position for at least one hour whereafter they could 
sit in a chair until 3 hours post-dose. No exercise was allowed in the first 3 hours 
after drug administration. A standard light lunch was served after a delay of at 
least 3 hours post-dosing. The evening meal was also light. Subjects stayed in 
CPSU until their cannula was removed after the 12 hour sample and returned the 
next morning to give a blood sample, collect a new urine bottle and have their BP 
and HR measured. This continued until 5 days post-dose. The subjects then 
underwent a washout period of at least 10 days and then repeated the procedure 
in exactly the same manner with the weight-adjusted dose. 
3.2.4 Blood Sampling 
Blood was taken for plasma perindopril, perindoprilat, renin, aldosterone 
angiotensin I concentrations and the level of ACE-activity. Plasma protein binding 
studies were not originally planned in the protocol but were subsequently 
performed. Blood sampling was at 0，0.5，1，1.5，2, 3，4，6, 8，12, 24, 48，72, 
96 and 120 hours for drug concentrations and 0，2，4，6，8，12, 24, 48，72, 96 and 
120 hours for hormone levels. The samples were centrifuged at 3000 rpm within 
15 minutes of collection and stored at -20°C prior to assay. 
3.2.5 Urine Sampling 
Urine was collected into bottles containing 2 g of boric acid as a 
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preservative. Collections were made over the following time periods: 0，0-4，4-8， 
8-12，12-24, 24-48, 48-72, 72-96 and 96-120 hours. After mixing to ensure 
homogeneity, a 10 ml aliquot was taken and stored at -20T： prior to assay for 
perindopril and perindoprilat. 
3丄6 Blood Pressure and Heart Rate 
Blood pressure and heart rate were measured at 0，4，6，8，12, 24, 48，72, 
96 and 120 hours in both the supine and standing positions. 
3 . 2 . 7 Non-invasive Haemodynamic Monitoring 
Non-invasive haemodynamic monitoring was not originally included in the 
protocol but due to the subsequent acquisition of the necessary equipment it was 
performed as an additional observation with minimal disturbance of the volunteers. 
It was performed after the 4 mg dose only at the following time points: prior to 
dosing and at 0.5, 1，1.5，2, 3，4，6，and 8 hours post dose. Subjects were 
monitored for a period of 5 minutes in the supine position and 5 minutes in the 
standing position before each blood sample was taken, up to 8 hours. Blood 
pressure and heart rate measurement were made at 1 minutes intervals throughout 
the recording period. However, not all subjects consented to this procedure and 
data were obtained from only 9 of the 22 possible subjects. The characteristics of 
the subjects who consented to haemodynamic monitoring are shown in Table 3.2. 
All of the Chinese but not all of the Caucasians were monitored for the full 8 hour 
period. A light meal was allowed at 3 hours post-administration of perindopril and 
all subjects ate during the the 3-4 hour period. 
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Table 3.2: Characteristics of the groups that underwent non-invasive 
haemodynamic monitoring (mean 士 SD plus range). 
Race n M:F Age (yr) Weight (kg) Height (cm) 
Chinese 4 1:3 29 土 8.7 57 士 10 159 土 5.3 
(21 -41) (49 -70) (155:167) 
Caucasians 5 4:1 29 ± 10 74 土 8.8 177 士 8.9 
(22 - 40) (64 - 81) (176 ~ 192) 
3.2.8 Analysis of Plasma Samples 
Determination of perindopril and perindoprilat in the plasma was achieved 
using radioimmunoassay (RIA). The assay was developed by the Netherlands 
Organisation for Applied Scientific Research (TNO), in Zeist，the Netherlands. 
Although I was unable to work on the assay myself, I was able to travel to the 
Netherlands and study the procedure. 
The antiserum was prepared by coupling the lysine analogue of 
perindoprilat (S-11453) to bovine serum albumin (BSA) via the dinitrodifluoro-
benzene (DNFB) conjugate. Rabbits were injected subcutaneously at 10 different 
sites with 1 mg of the immunogen suspended in Freund's complete adjuvant 
(Difco). After 24 weeks, antiserum titres between 5,000 and 120,000 were 
obtained. Blood from the rabbits with the highest antiserum titre and specifity 
was pooled and stored at -80°C. 
The radioligand was the p-hydroxyphenyl derivative of S-11453 (SI 1868) 
and was prepared using Bolton-Hunter reagent and iodinated using the Chloramine 
T reaction. The radioligand was purified using chromatography on Dowex AG 1 
X 2 (200-400 mesh; Biorad). 
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Perindoprilat could be directly quantified using this method. Perindopril 
could be measured using the same assay, after chromatographic separation and 
saponification. The limit of detection of the assay is 0.15 - 0.5 ng/ml. The intra-
and inter-assay coefficients of variation were both < 6 % (Van Den Berg, 
Resplandy, Bie, Floor, Bertrand & Arts，1991). 
3.2.9 Hormone and Enzyme Assays 
These assays were all performed by I.R.I.S. Plasma ACE activity was 
measured using the method described by Cushman & Cheung (1983). The method 
utilises a sensitive spectrometric assay which measures the rate of production of 
hippuric acid from hippuryl-L-histidyl-L-leucine (HHL) through the action of the 
angiotensin-converting enzyme. HHL is an N-terminal protected tripeptide, 
resistant to degradation by other tissue peptidases. The results were expressed in 
mU/ml (1 ACE unit = 1 fimol of hippuric acid generated per minute at 37''C). 
Aldosterone was measured by radioimmunoassay with ⑵i-aMosterone (Kit 
SB - ALDO 2, International CIS-BP 32 - 91192 Gif sur Yvette, France). The 
quantification limit was 15 pg/ml. 
Both angiotensin I (Al) and plasma renin activity (PRA) were measured by 
radioimmunoassay with ^i-Ag (Kit SB-REN-2, International CIS-BP 32-91192 Gif 
sur Yvette, France). Al was assayed at 3TC and PRA was calculated as: 
rng 3TC - ng 4。C、x 1.12 
Time of incubation 
and expressed as ng rnl'^h'^ The quantification limit was 0.2 ng/ml of AL 
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Plasma protein binding was determined at 37T by an equilibrium dialysis 
technique using Dianorm R apparatus. 3H-perindopril and 3H-perindoprilat were 
supplied by CEA (France). 
J^ATA ANALYSIS AND STATISTICAL METHODS 
3.3.1 Pharmacokinetic Analysis of Plasma 
The individual plasma concentration versus time profiles for perindopril and 
perindoprilat were determined by model dependant methods using the SIPHAR 
pharmacokinetic modeling programme. Both perindopril and perindoprilat were 
fitted to a triexponential model (see section 2.6.1 of General Methodology). 
3.3.2 Pharmacokinetic Analysis of Urine 
The cumulative amount of compound excreted in urine at time t (Ae^ ) was 
expressed in ^g or as a percentage of the dose administered. The renal clearance 
(CLr) was calculated from the ratio Aet/AUQ, the time ^ corresponds to the the 
duration of the collection period. 
3.3.3 Pharmacodynamic Analysis of Hormone Data 
The analysis of ACE-activity, plamsa renin-activity, angiotensin I and 
aldosterone concentrations are described in the General Methodology (Section 
2.6.2). 
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Analysis of Haemodynamic Monitoring Data 
The data generated by the non-invasive haemodynamic monitoring was 
imported into Quattro Pro (Version 4.0; Borland, 1992) for analysis. The mean 
of the last 3 minutes in the sitting position and in the standing position were taken 
for each subject at each time point. The data was then combined for statistical 
analysis as a group and as Chinese v .^ Caucasians. Due to the wide inter-subject 
variation in haemodynamic data, the results were then expressed as the percentage 
change from the baseline for each time point. The initial 0 hour values for each 
subject being taken as 100%. The t values for these changes were then calculated 
to denote any significance. Parameters with significant t values in one group were 
then further compared by an independant t-test with the data from the other group, 
using the SigmaPlot software programme (Version 5.0，Jandel Scientific; 1993). 
An analysis of variance did not seem useful, given the small number of subjects 
in each ethnic group. 
3.3.5 Statistical Analysis 
See section 2.7 in General Methodology for full details of statistical 
analysis. Chinese and Caucasian subjects were compared using the unpaired 
student t-test and the Mann-Whitney U test. The effects of the two doses were 
compared within individuals using the Paired Student t-Test and the Wilcoxin 
Signed Rank Test. 
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PHARMACOKINETIC RESULTS 
3《1 Pharmacokinetics of Perindopril in Plasma 
Mean plasma concentration versus time is presented in Figure 3.1. A 
comparison between the mean plasma concentrations for the Caucasian subjects in 
this study and the Caucasians in the study conducted by Lecocq et al. (1990) is 
shown in Figure 3.2. Mean area under the curve (AUG), time to maximum 
concentration ( t^J , and maximum concentration (C^J are listed in Tables 3.3-
3.6. 
After administration of the drug the plasma concentrations peaked by one 
hour and then declined rapidly with a biphasic elimination phase allowing 
calculation of absorption, alpha and beta half-lives. Elimination of perindopril 
occurred so quickly that 8 hours after the 4 mg dose the mean plasma 
concentration represented only 2.1% of the peak concentration in Caucasians, and 
1.5% in Chinese. By 12 hours the percentages were down to 0.7% and 0.4% in 
Chinese and Caucasians respectively. The pattern was similar when the dose was 
adjusted for weight, in Caucasians the plasma concentration was at 2.6% of the 
peak at 8 hours and 1.0% at 12 hours. In Chinese it was at 0.9% at 8 hours and 
0.6% at 12 hours post-dose. 
The plasma concentration v«y. time curves were similar in Chinese and 
Caucasians. However, the Chinese exhibited a significantly shorter t^ x^ after the 
4 mg dose (0.7 土 0.1 v^y. 1.1 土 0.1，p< 0.05) and the 4 mg/70 kg dose (0.7 土 
0.1 v .^ 1.2 士 0.2，p< 0.05 ). C咖X tended to be higher in the Chinese subjects 
when the dose was not adjusted for weight (99.1 土 14.3 67.4 ± 6.3), however 
78 
^Sure 3.1: Mean plasma concentration time curves for perindopril in 
Chinese and Caucasians after a) perindopril 4 mg and b) perindopril 4 mg/70 kg. 
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^Sure 3.2: Mean plasma concentration time curves for perindopril in 
Chinese and Caucasians after a standard 4 mg dose compared with the data on 
French Caucasians after the same dose published by Lecocq et al (1990). 
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this difference did not reach significance by the parametric test and was borderline 
by the Mann-Whitney U test (p=0.04). 
AUCt and AUCoo were similar between the groups after both doses. 
However, the Caucasians showed a significant increase in both parameters after 
the weight-adjusted dose (AUQ: 121.7 士 6.5 v .^ 166.7 士 17.1，p< 0.05; 
AUCoo： 123.8 士 7.2 171.6 土 17.4, p < 0.01). 
The half-life of the absorption phase was significantly shorter in the 
Chinese subjects after both doses, particularly so after the weight-adjusted dose 
P < 0.01). The half-life of the alpha phase (t/J and the half-life of the beta 
phase (t,^ )^ did not differ significantly, although there was a tendancy towards a 
longer t.^ ^ in the Caucasian group, particularly after the weight-adjusted dose. The 
Chinese exhibited a significantly longer after the weight-adjusted dose, in 
comparison with their previous values. The mean residence time (MRT) was also 
longer in Caucasians, the difference being significant after both doses, but more 
so after the adjusted dose (p< 0.01). 
Neither clearance (CL) nor volume of distribution (Vj) demonstrated an 
ethnic difference between the two groups, but there was a substantial decrease in 
the CL value in Caucasians when the dose was adjusted for weight (p< 0.01). 
3.4.2 Pharmacokinetics of Perindopril in Urine 
In both Chinese and Caucasians perindopril was almost completely excreted 
within the initial eight hour period, see Figure 3.3. The total amount of 
unchanged drug excreted in the urine represented 18.6 土 5.4% and 21.0 士 6.1% 
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of the dose after 4 mg and 4 mg/70 kg respectively in the Chinese group and 18.3 
土 5.8% and 18.7 士 3.2% respectively in the Caucasian group. There was no 
statistical difference between the two groups, Table 3.7 gives the pharmacokinetic 
parameters for perindopril in urine after both doses. 
3.4.3. Pharmacokinetics of Perindoprilat in Plasma 
Conversion of perindopril to perindoprilat was rapid, with perindoprilat 
first appearing in the plasma within 30 minutes of perindopril administration. 
Subsequently, it decayed in a multi-exponential manner with three distinct phases 
being detectable. As with the prodrug, it was possible to calculate a half-life for 
the absorption phase and two elimination phases. Although it did not reach 
statistical significance, the plasma concentration of perindoprilat in Chinese 
subjects was higher than in Caucasians, the data did not converge until 24 hours 
post-dose. However, after the dose was adjusted for weight, the difference was 
markedly smaller (see Figure 3.4). t^ ax was similar regardless of race. The 
pharmacokinetic parameters for perindoprilat are presented in Tables 3.8-3.11. 
AUCt and AUCoo showed no difference between races or doses. Both t.^ b^ and 
were comparable in the two groups. iVi^  was significantly longer in the 
Caucasian volunteers when the dose was not adjusted for weight, but this 
difference was not evident after the second dosing. As would be expected, MRT 
showed the same disparity. Both iVi^  and MRT were statistically different 
between doses for the Chinese group.The difference in plasma CL was highly 
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^Sure 3.3: Mean cumulative excretion of perindopril in urine in Chinese and 
Caucasians after a) perindopril 4 mg and b) perindopril 4 mg/70 kg. 
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Table 3.7: Pharmacokinetic parameters of perindopril in urine in Chinese 
subjects after perindopril 4 mg and perindopril 4 mg/70 kg. 
I 4 mg Dose 4 mg/70 kg Dose 
Subjects j Ae Fe CLr Ae Fe CLr 
I (Mg) (%) (ml.min-') (/ig) (%) (ml.min') 
4 j 622.9 18.7 82.0 500.0 15.0 119.2 
5 j 644.5 19.3 89.4 450.6 18.0 119.4 
6 j 290.9 8.7 57.0 313.1 10.7 80.8 
7 j 573.4 17.2 83.0 458.0 15.7 48.7 
9 j 962.4 28.8 229.8 693.6 27.7 133.8 
10 j 344.6 10.3 53.4 386.9 18.5 79.1 
14 j 877.5 26.3 36.1 761.8 30.4 66.3 
15 j 679.9 20.4 74.1 819.6 24.6 79.0 
16 j 440.2 13.2 43.9 847.8 25.4 65.7 
17 j 569.9 17.1 51.9 526.6 18.0 69.9 
19 I 1105.0 33.1 91.8 1133.0 33.9 116.1 
20 j 352.6 ^ 40.4 348.6 13.9 45.2 
Mean: I 622.0 18.6 77.7 603.3 21.0 88.9 
SD: I 255.1 7.6 51.8 248.1 7.2 28.1 
Sem: ！ 73.6 2.2 14.9 71.6 2.1 8.1 
I I II I 
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T a， P h a r m a c o k i n e t i c parameters of perindopril in urine in Caucasian 
subjects after perindopril 4 mg and perindopril 4 mg/70 kg. 
I 4 mg Dose 4 mg/70 kg Dose 
Subjects ‘ Ae Fe CLr Ae Fe CLr 
！ O^g) I W I (ml.min-i) O^g) (%) (ml.min') 
1 j 524.8 15.7 78.9 708.3 15.4 63.6 
2 j 733.6 22.0 88.0 455.0 18.2 63.0 
8 j 748.0 22.4 142.6 619.8 21.2 77.9 
11 j 329.2 9.9 53.1 394.1 13.5 59.1 
12 j 144.4 4.3 25.4 691.8 18.4 99.8 
13 j 506.8 15.2 57.2 489.5 13.0 34.7 
21 j 297.6 8.9 40.9 706.7 16.9 67.2 
23 j 572.3 17.1 76.9 656.9 22.5 66.3 
24 I 1047.0 31.4 138.8 474.0 16.2 48.4 
25 j 1206.0 36.3 116.1 1060.0 31.8 61.1 
Mean: j 611.0 18.3 81.8 625.6 18.7 64.1 
SD: j 332.2 10.0 40.1 192.0 5.5 17.1 
SEM: ！ 105.0 3.2 12.7 60.7 1.7 5.4 
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significant between the races, but once again, only when the dose was not adjusted 
for weight (p< 0.001). The V^ did not differ statistically. 
Pharmacokinetics of Perindoprilat in Urine 
The pharmacokinetic parameters of perindoprilat in urine are presented in 
Table 3.12. The cumulative excretion of perindoprilat in mg is shown in Figure 
3.5. At the end of the initial 24 hour period, the amount of perindoprilat excreted 
in the urine represented at least 73% of the total dose excreted. There was no 
statistical difference in any of the urinary parameters between the two groups. 
3.5 PHARMACODYNAMIC RESULTS 
3.5,1 Angiotensin Converting Enzyme Inhibition 
Figure 3.6 shows ACE-inhibition and ACE-activity after both doses. 
Figure 3.7 shows ACE-inhibition plotted against plasma perindoprilat 
concentration after both doses. Tables 3.15 and 3.16 give the mean values for the 
pharmacodynamic parameters in Chinese and Caucasians. A dose response 
relationship was noted in Chinese subjects who achieved 88 % inhibition after a 4 
mg dose and 84% after the smaller weight-adjusted dose. Regardless of dose, 
was reached within 6 hours of administration in the Caucasian group and 5 hours 
in the Chinese group. When ACE-inhibition is plotted against perindoprilat 
concentration, it can be seen that the dose of perindopril given was not sufficient 
to induce 100% inhibition of ACE. 
90 
^Sure 3.4: Mean plasma perindoprilat concentrations v^.time curves in Chinese 
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3.5: Mean cumulative excretion of perindoprilat in urine in Chinese and 
Caucasians after a) perindopril 4 mg and b) perindopril 4 mg/70 kg. 
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Table 3.13: The pharmacokinetic parameters of perindoprilat in urine in Chinese 
subjects after perindopril 4 mg and perindopril 4 mg/70 kg. 
j 4 mg Dose 4 mg/70 kg Dose 
Subjects ！ Ae Fe CL, Ae Fe CL, 
j pig) (%) (ml.min') (/ig) (%) (ml.min"^) 
4 j 361.7 11.7 85.2 422.8 13.7 85.7 
5 j 642.3 20.8 68.8 581.1 25.1 87.6 
6 j 595.4 19.3 93.4 343.1 12.7 40.2 
7 j 776.3 25.2 121.4 615.8 22.8 109.8 
9 j 428.4 13.9 79.0 193.9 8.4 36.4 
10 j 383.3 12.4 82.2 212.2 11.0 55.3 
14 I 392.3 12.7 61.3 489.3 21.2 151.6 
15 j 306.4 9.9 89.1 319.5 10.4 124.7 
16 j 285.7 9.3 94.9 322.7 10.5 123.1 
17 I 394.7 12.8 215.0 395.5 14.7 214.0 
19 j 258.9 8.4 88.8 380.4 12.3 79.0 
20 I 607.9 19.7 85.9 387.1 16.7 101.8 
Mean: ！ 452.8 14.7 97.1 388.6 15.0 100.8 
SD: I 163.1 5.3 39.9 128.0 5.4 49.8 
SEM: I 47.1 1.5 11.5 37.0 1.6 14.4 
I I 
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Table 3.14: The pharmacokinetic parameters of perindoprilat in urine in 
Caucasian subjects after perindopril 4 mg and perindopril 4 mg/70 kg (* = 
unavailable value). 
I 4 mg Dose 4 mg/70 kg Dose 
Subjects I Ae Fe CL, Ae Fe CL, 
！ Qig) (%) (ml.min•丨） (/ig) (%) (M.mm') 
1 j 402.1 13.0 76.9 992.0 23.4 149.9 
2 j 651.2 21.1 92.7 445.0 19.2 85.1 
8 j 400.7 13.0 131.5 260.0 9.6 162.3 
11 j 341.7 11.1 64.4 263.8 9.8 55.1 
12 j 313.3 10.2 58.1 281.3 8.1 36.9 
13 j 308.2 10.0 50.2 412.8 11.9 51.8 
21 j 235.9 7.7 58.4 399.9 10.4 62.1 
23 j 520.9 16.9 76.4 388.9 14.4 85.2 
24 j 452.8 14.7 ** * 376.2 13.9 154.8 
25 j 536.5 17.4 171.3 569.0 18.5 101.6 
Mean: I 416.3 13.5 115.6 402.7 28.0 87.8 
SD: I 125.9 4.1 99.1 254.4 44.8 43.6 
SEM: I 39.8 1.3 31.3 80.5 14.2 13.8 
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Table 3.15: Pharmacodynamic parameters (ACE-inhibition) in Chinese subjects 
after administration of perindopril 4 mg and perindopril 4 mg/70 kg (* indicates 
that the t l ^ IS given as the median, minimum and maximum values). 
j 4mg Dose 4 rog/70 kg Dose 
Subjects I Ux tUx AUCIt I24 tUx AUCIt 
I (%) (h) (%/h) (%) (%) (h) (%/h) (%) 
4 [ 92 6.0 4027 66 90 6.0 3781 57 
5 j 92 4.0 3382 62 89 4.0 2964 55 
6 j 84 8.0 3652 60 82 6.0 3231 66 
7 I 93 4.0 3465 64 92 3.0 3397 62 
9 j 86 6.0 3270 60 76 8.0 2715 48 
10 j 83 6.0 3130 62 69 24.0 3759 69 
14 j 94 4.0 3606 67 90 4.0 3269 60 
15 I 84 8.0 3843 65 79 8.0 3235 62 
16 ！ 81 8.0 4316 68 78 8.0 3615 63 
17 j 87 6.0 3261 53 88 4.0 3403 59 
19 I 84 6.0 3177 48 85 8.0 4466 73 
20 丨 97 3.0 3831 67 89 4.0 3569 62 
Mean: I 88 5.8" 3580 62 84 7.3* 3450 61 
SD: I 5.2 1.7* 368 6.1 7.0 5.6* 446 6.6 
SEM: ！ 1.5 0.5* 106 1.8 2.0 1.6* 129 1.9 
I I I • I il I I I 
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Table 3.16: Pharmacodynamic parameters (ACE-inhibition) in Caucasian subjects 
after administration of perindopril 4 mg and perindopril 4 mg/70 kg (* indicates 
that H ^ is given as the median, minimum and maximum values). 
I 4 mg Dose 4 mg/70 kg Dose 
Subjects I 
丨 Uc tUc AUCIi I24 Ux tUx AUCI, I24 
! W (h) (%/h) (%) (%) (h) (%/h) (%) 
1 j 83 8.0 3977 76 88 4.0 2929 50 
2 I 93 4.0 3617 63 89 4.0 3261 57 
8 j 85 8.0 3328 68 70 8.0 2684 50 
11 [ 72 8.0 2357 51 76 6.0 2665 51 
12 j 80 6.0 3882 67 80 6.0 3371 56 
13 j 80 8.0 3978 67 78 12.0 3780 70 
21 j 82 4.0 3768 67 91 6.0 4206 75 
23 1 93 6.0 4773 74 86 6.0 3660 67 
24 ！ 87 6.0 3658 66 84 6.0 3247 63 
25 I 89 6.0 3118 54 84 6.0 3586 58 
Mean: I 84 6.4* 3646 65 82 6.4* 3339 60 
SD: ！ 6.6 1.6" 633 7.8 6.6 2.3* 492 8.8 






























































































































































































































































































3.7: Mean ACE-inhibition (%) plotted against mean plasma perindoprilat 
concentrations in Chinese and Caucasians after a) perindopril 4 mg and b) 
perindopril 4 mg/70 kg. 
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3-5.2 Angiotensin I (Al) 
Figure 3.8 shows the Al concentration in Chinese and Caucasians after both 
the standard 4 mg and the weight-adjusted dose of perindopril. The expected 
increase in Al levels was not seen in Caucasian subjects and did not achieve 
significance in Chinese subjects. The results showed a wide intra-subject variation 
but no significant difference between the two groups. Due to the erratic nature of 
the data, it is hard to discern any definite effect after either treatment. 
3.5.3 Aldosterone and Plasma Renin Activity (PRA) 
Figure 3.9 shows mean aldosterone and PRA concentrations in Chinese and 
Caucasians after both doses. Aldosterone was clearly depressed in both groups at 
8 hours post-dose but had returned to ks baseline levels by 48 hours, regardless 
of the dose given. The PRA data showed wide intra-subject variation making 
conclusions difficult. A slight rise was seen in Chinese subjects after the 4 mg 
dose but otherwise no distinct pattern was detectable. 
3.5.4 Plasma Protein Binding 
Human plasma albumin (HPA) was measured in the 0 hour plasma samples 
collected prior to dosing. The results are shown in Table 3.17. Levels of HPA 
were almost identical between the races, as were the percentages of both 
perindopril and perindoprilat bound to albumin. 
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风g鹏 3.8: Mean angiotensin I concentrations in Chinese and Caucasians after 
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风g鹏 3.10: Mean systolic blood pressure (SBP), diastolic blood pressure (DBP) 
and heart rate (HR) in supine Chinese and Caucasians after perindopril 4 mg and 
perindopril 4 mg/70 kg (*= p< 0.05 0 hour measurement). 
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3.11: Mean systolic blood pressure (SBP)，diastolic blood pressure (DBP) 
and heart rate (HR) in standing Chinese and Caucasians after perindopril 4 mg and 
perindopril 4 mg/70 kg. 
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3*17: Human plasma albumin (HPA) concentrations, perindopril (P) and 
penndoprilat (Pt) plasma binding levels in Chinese and Caucasians. 
HPA (g/1) P Binding (%) Pt Binding (%) 
Chinese 42.6 士 1.5 73.3 士 1.8 18.3 士 2.4 
Caucasians 41.4 士 4.6 74.2 土 1.7 18.8 士 2.0 
3.5.5 Blood Pressure and Heart Rate 
Mean systolic blood pressure, diastolic blood pressure and heart rate in the 
supine and standing positions are shown in Figure 3.10 and 3.11 respectively. 
Maximum reduction in SBP and DBP compared to pre-dose levels was seen 
between 4 and 6 hours in both groups, regardless of dose. However, after the 
weight-adjusted dose, no significant fall was seen in the Caucasian SBP, although 
the values for the Chinese group were significantly reduced at 4 and 8 hours. 
DBP was significantly reduced at 4 hours and 8 hours in the Caucasian subjects 
and at 8 hours in the Chinese. 
HR was significantly raised in the Chinese subjects at 12 and 24 hours after 
the 4 mg dose of perindopril, however this trend was no longer significant after 
the weight-adjusted dose. Caucasians showed a significant reduction in HR at 4 
and 8 hours. 
There were no significant differences between the two groups in either BP 
or HR response. 
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3.5.6. Safety and Tolerance 
Clinical tolerance of perindopril throughout the study was good. Only one 
subject complained of dizziness in the evening, 48 hours after the weight-adjusted 
dose, which continued into the following day. 
Blood pressure and heart rate stayed within normal limits in every subject 
throughout the study. 
3.5.7 Non-invasive Haemodynamic Monitoring 
In view of the small number of subjects, the data were analysed for both 
groups combined (n=9) and also comparing the Chinese and the Caucasians (n=4 
and 5 respectively). The results given refer to the combined data values, except 
when specific reference is made to the racial groups. The combined mean data 
values are shown in Tables 3.18 and 3.19. The percentage change from baseline 
in the combined values is shown in Figures 3.12-3.16. The percentage change 
from baseline in Chinese v .^ Caucasians is shown in Figures 3.17-3.18. 
Supine SBP began to drop at 2 hours in the Chinese group (the data from 
one subject is missing) and reached a trough at 3 hours, (-5 士 7%) whereas the 
Caucasian SBP did not drop until 3 hours, whereupon it dropped to the same 
degree as that of the Chinese (See Figure 3.12 & Table 3.18). Standing SBP rose 
in Caucasians at 1 hour by 6% but had almost returned to its original level by 3 
hours (see Table 3.18). Chinese standing values showed a peak at 3 hours, 
however this reflected a rise of 10% in one subject only. None of the above 
changes reached statistical significance. 
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D B P was reduced by 11% at 3 hours in the supine position, but unchanged 
in the standing position (see Table 3.18). At 6 hours it was reduced both standing 
and supine by 10%. Supine D B P was reduced to a greater extent in the Caucasian 
subjects (3 hour supine value, -15 士 4% vs. -5 士 6%) but standing values were 
slightly lower in the Chinese (Figure 3.12). Again none of these changes reached 
statistical significance. 
Supine M B P showed a slight tendency to rise at 1 and 1.5 hours and 
subsequently dropped by 6% at 6 hours (see Table 3.18). The pattern was similar 
in the standing position, although less marked. The reduction was more obvious 
in the Chinese group and sustained for longer (see Figure 3.12 & Table 3.18). 
Again the supine and standing data were similar, but standing values from 4 to 8 
hours tended to be lower in the Chinese group, a rise occurred between 0 and 1.5 
hours in the Caucasians, but this reflected a large rise in just one subject of 48% 
in the supine position and 31% when standing, and so was not significant. At 6 
hours, both supine and standing values were lower in the Chinese subjects than in 
the Caucasians (supine: -9.14 士 4.6 vs. 0.97 士 11.1; standing: -9.44 土 3.3 vs.-
3.82 士 0.91)，although not significantly so. 
Mean H R appeared to drop to almost 10% below the baseline value 
between 0.5 and 2 hours, when it started to rise reaching a peak at 6 hours of 
nearly 10% above the baseline (see Table 3.18). This pattern was reflected in 
both the supine and standing data. The pattern was nearly identical in both 
Chinese and Caucasians (see Figures 3.12, 3.13 and 3.14). 
TFI varied only within 4% of its initial value throughout the monitoring 
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3.12: Mean supine and standing systolic (SBP), diastolic (DBP), mean 
(MBP) blood pressure and heart rate (HR) (measured by the Datascope Accutor 
1) in Chinese (n=5) and Caucasians (n=4) after an oral dose of perindopril 4 mg. 
The data is displayed as the percentage change from the baseline value. 
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3.14: Mean supine and standing heart rate (HR), stroke index (SI), 
cardiac index (CI), and ventricular ejection time (VET) in Chinese (n=5) and 
Caucasians (n=4) after an oral dose of perindopril 4 mg. The data is displayed 
as the percentage change from the baseline value. 
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period (see Tables 3.19). 
SI rose steadily from 0 hour, increased sharply between 3 and 4 hours 
(supine 22.3 土 14.7%; standing 27.1 士 27.3% at 4h) and subsequently dropped 
to close to its pre-dose levels at 8 hours (see Table 3.19 and Figures 3.14 and 
3.15). 
A sharp rise in CI was noted, starting at 4 hours post-dose in both Chinese 
and Caucasians, regardless of position (see Figure 3.14). It rose substantially in 
all 9 subjects, but did so to a larger extent in the Caucasian group than in the 
Chinese. Again this change was greatest at 4 hours (supine 32 ± 21 18 土 
13%; standing 44 ± 23% vs. 23 士 12%). The values were similar at 0 and 3 
hours in both groups (see Figures 3.14 and 3.16 and Table 3.19). 
The systemic vascular resistance index (SVRI) responses both supine and 
standing were virtually identical and showed a decrease starting at 2 hours post-
dose which was maximal at 4 hours (see Figure 3.17 & Table 3.18). In both the 
supine and standing positions it had decreased by 26% of its baseline values by 4 
hours post-dose (supine 26.2 士 11.1%，p=0.0003; standing 27.7 士 11.4%， 
p=0.0002) and remained reduced up to 8 hours (see Figure 3.18). There is little 
difference in the change in supine and standing SVRI between the two groups, 
with the exception that the supine and standing values drop by a greater proportion 
in the Caucasian group than in the Chinese, reaching a trough at 4 hours (supine 
-30 士 12% vs. -22 士 10%; standing -30 士 14% vs.-25 士 7%). The drop was 
significant in both groups at 4 and 6 hours (see Table 3.18). 
VETI rose sharply from its initial values at 0 hour to peak sharply at 3 
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hours at 6% above its pre-dose value in the standing position. Supine values did 
not rise until 4 hours, and then by 3% (see Table 3.19 and Figure 3.18). Again 
the standard deviation of the changes was large. No inter-group variation was 
noted (see Table 3.5). 
3.6 DISCUSSION 
The pharmacokinetics of perindopril and perindoprilat in plasma proved 
remarkably difficult to fit to any of the standard compartmental models. The data 
itself was often erratic, showing several peaks and troughs in the plasma 
concentration v^. time curves. In some subjects this necessitated the deletion of 
several, presumably aberrant, data points. The terminal elimination half-life of 
perindopril is generally reported as between 1.5 and 3 hours (Lees & Reid，1985; 
Funck-Brentano, Lecocq, Jaillon & Devissaguet，1989; Lecocq, Funck-Bretano, 
Lecocq, Ferry, Gardin, Devissaguet & Jaillon，1990). However, the terminal 
elimination phase is characterised by extremely low concentrations of the drug 
representing a tiny fraction of the original dose and sometimes leading to the 
calculation of an incorrectly long In fact, Lecocq et al. (1990) state that they 
could reliably calculate the of perindoprilat in only two of their twelve 
subjects. Devissaguet et et al (1990) report the to be 44 土 18 hours and 
admit to obtaining poor fits. They suggest that this prolonged terminal phase is 
an artifact of analytical origin. They offer one possible explanation, the 
contamination of the prodrug samples with perindoprilat bound to ACE. As the 
assay for perindopril entails chromatographic separation from its metabolites, prior 
Chapter 3 - The Perindopril Study 121 
to hydrolysis of the samples and determination of the active metabolite (Van Den 
Berg et al•，1991)，it seems possible that some of the proteins present in the 
samples of the parent drug may contain some diacid bound to ACE. In their paper 
describing the assay, Van den Berg et al (1991) do make specific reference to this 
contamination but say that this effect could be eliminated by heat treatment of the 
samples before applying them to the chromatography column. However, cross 
contamination of both ester and diacid is technically possible during the 
chromatography process. This could lead to erroneously high concentrations. The 
results of this study also support the theory of an analytical artifact concerning the 
terminal elimination phase. Our subjects were given oral closes on two separate 
occasions. In some subjects, plasma concentrations were undetectable at 24 hours, 
whilst in others a prolonged terminal elimination phase in excess of 50 hours was 
clearly in evidence. When the results of the two doses were compared, it was 
found that both phenomenons could occur in the same subject. W e concluded tha 
that the plasma concentrations detected after 12 hours were probably erroneous. 
In addition, by 12 hours the concentration of perindopril in plasma was 0.7% of 
the original dose in Chinese and 0.4% in Caucasians, it therefore seemed justified 
to analyse the perindopril concentration between 0 and 12 hours only. For many 
of the subjects, the last measurable concentration was at 12 hours anyway. This 
approach allowed for a reasonable estimation of the duration of all three 
exponential phases. 
The pharmacokinetics of perindopril and perindoprilat were found to be 
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both the 4 mg and the 4 mg/70 kg doses, reaching peak concentrations in 
approximately one hour. Elimination was also rapid with plasma concentrations 
becoming negligible 6 hours after dosing. Conversion from perindopril to 
perindoprilat was swift, with the metabolite appearing in the blood within 30 
minutes of perindopril administration. Tables 3.20 and 3.21 compare some of the 
pharmacokinetic parameters determined in this study with some published data. 
When the plasma concentration time curves for Chinese and Caucasians are 
plotted against the data published by Lecocq et al. (1990)，which was obtained in 
French Caucasians, the similarity between the two groups of Caucasians can 
clearly be seen (see Figure 3.2). The only pharmacokinetic parameters which 
differed from those already published were renal clearance and cumulative urinary 
excretion of perindopril and perindoprilat. Table 3.20 shows that the renal 
clearance of perindopril is higher than has previously been reported in both 
Chinese and Caucasians. There is no obvious reason for this difference. Poor 
subject compliance would mean loss of urine and therefore a lower renal 
clearance. All of the urine collected was measured in glass measuring columns 
accurate to within 10 ml and subsequently stored in a -20。C freezer until analysis. 
However, the temperature of the specimens could not be controlled during the 
collection period. The urine was divided into 4 hour collections for the initial 12 
hour period and those collections were made in an air conditioned clinic in a 
temperature of approximately 22。C. However, the subsequent collections were 
made over one 12 hour and four 24 hour periods in the subjects' workplace or 
home. These locations could have reached temperatures of up to 35°C during the 
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season when the bulk of the study was performed. It is unknown how stable 
perindopril and its metabolites would be in urine under such conditions. The 
additive in the bottles was boric acid and this is a fairly weak acid, which 
ultimately did not lower the pH of the samples below 5. Whilst recovery of 
unchanged perindopril was higher than previously reported, it is interesting to note 
that the cumulative recovery of perindoprilat was lower. As it is unlikely that 
there is any difference in the metabolism of the parent drug, this may be due to 
further breakdown of the drug during the collection period. Of course, the above 
variations could be due in part to differences in assay techniques. 
Several statistically significant differences in the pharmacokinetic 
parameters of perindopril emerged between Chinese and Caucasians. Firstly, t^狀 
was significantly shorter (p< 0.05) in Chinese after the 4 mg dose. Although it 
tended to be higher after the weight-adjusted dose as well, the difference did not 
reach statistical significance. This parameter is model independant and so is not 
subject to variances due to the fitted model. No difference was found in the rate 
of conversion of perindopril to perindoprilat (i.e. perindoprilat t^ x^ and t,/,ab) 
suggesting that any genuine difference would lie in the slightly faster absorption 
of the parent drug in Chinese, although it is difficult to propose a reason for this 
disparity. Perhaps differences in the acidity of stomach or rate of gastric emptying 
could be involved, but no data exists to support such theories. However, as this 
difference did not reach significance when the dose was adjusted for weight, 
further investigation with a larger study population would be required to prove 
significance. Whether this data represents a genuine ethnic difference or not, it 
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can have no relevance to the therapeutic usage of perindopril. 
A shorter was also demonstrated in the Chinese subjects. This was 
significant after both doses, even more so after the weight-adjusted dose 
(p< 0.01), and by both parametric and non-parametric tests. When taken with 
the shorter t^ x^, this difference could once again reflect a faster absorption of the 
parent drug in Chinese subjects. However, it could also be partially due to the 
method used to fit the data. The plasma concentration vj. time curves peaked 
very sharply after administration for both perindopril and perindoprilat, this made 
an accurate fit of all three phases extremely difficult. A good fit of the 
distribution and elimination phases was considered to be most important and the 
best fit of the absorption phase often meant a poor fit of the other two phases and 
vice versa. An accurate evaluation of the absorption phase between the ethnic 
groups was not possible with any of the compartmental models tried. In addition 
to this, the blood sampling schedule did not allow for a proper characterisation of 
the absorption phase, the first sample being at 0.5 hours meant that some subjects 
had already reached t^ x^- In short, this parameter cannot be considered to be 
reliable. 
Perindopril C^ x^ was significantly higher in the Chinese group after 4 mg 
of perindopril (p< 0.05 by the Mann-Whitney test). It did not reach significance 
by the student t-test, probably because the data is skewed towards the higher 
values. However, when dealing with sample numbers this size it is may be 
incorrect to make such assumptions about the normality of the population. 
Whether significant or not, it is undoubtably due to the larger dose per body 
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weight which the Chinese subjects received. No such difference can be seen when 
the dose is adjusted for weight. 
The only other difference in the pharmacokinetics of the prodrug is in mean 
residence time (MRT). M R T was significantly different after the 4 mg dose 
(P< 0.05) and the weight-adjusted dose (p< 0.01). M R T is calculated from the 
summation of the coefficients of the three phase divided by the exponential of each 
phase squared. As no significant difference was found in the or ti� of 
perindopril between the groups, it may be that the difference in the could be 
influencing this result. 
Perindoprilat pharmacokinetics were the same in both Chinese and 
Caucasians when the dose was adjusted for weight. However when the Chinese 
received the larger 4 mg dose, several statistically significant differences did 
appear. The elimination half-life was significantly longer in the Caucasian 
subjects. This is not what one would expect, considering the lighter body-weight 
of the Chinese. However, clearance is also signifcantly faster in the Chinese 
subjects. This would explain the shorter t,灿，but there is no reason why the 
plasma clearance should be any faster in the Chinese, especially as there was no 
difference on the second occasion. Clearance is calculated as dose divided by 
AUCoo. The dose on this occasion was the same for both groups and A U C „ was 
larger in the Caucasian group. In addition, several of the Chinese subjects 
exhibited a very small AUCoo which would lead to the calculation of a larger 
clearance value. M R T was also significantly longer in the Caucasians, this is of 
course due to the longer in this group. The longer in Caucasians is hard 
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to explain, however, as it was not evident after the weight-adjusted dose it is 
unlikely to be of any significance. 
A dose-response effect was noticed for the Caucasian subjects with A U Q 
and AUCoo, with a highly significant increase occurring after the weight-adjusted 
dose. As the weight-adjusted dose was also 4 mg in the Caucasian subjects, this 
result seems somewhat strange. Closer examination of the data reveals that the 
difference is due to a large increase in two subjects who, being quite large 
individuals, had weight-adjusted doses of 5.5 and 5 mg respectively. 
The pharmacodynamic results also correlate well with those reported in the 
literature. Maximal ACE-inhibition was reached within 8 hours of perindopril 
administration, regardless of race or dose. However, 100% inhibition of A C E 
was not achieved with the doses administered for this study and so saturable 
binding to A C E was not seen. 
Other authors have reported a dose-dependant rise in plasma renin-activity 
(PRA) following doses of 4 mg and over (Lees & Reid, 1987; Lees, Green & 
Reid, 1988; Thuillez, Richard, Richer, Loueslati, Ferret, Auzepy & Giudicelli， 
1988). However, this rise was only in evidence in the Chinese subjects, who 
showed a tendency towards higher values after the 4 mg dose. No salt restriction 
was imposed on the subjects in this study, but a significant increase in PRA is 
reported in other studies whether a salt-restriction is imposed or not. The lack of 
a rise cannot be ascribed to inter-subject variation. 
The small effect of perindopril on the blood pressure of both groups is in 
accordance with that reported in other studies conducted on healthy volunteers 
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(Thuillez et al, 1988; Funck-Brentano et al, 1989; Waeber, Nussberger, Ferret, 
Santoni & Brunner, 1989). However, some significant changes in blood pressure 
and heart rate were noted in this study. Systolic blood pressure was significantly 
reduced in the standing position in both Chinese and Caucasians. However, in the 
Caucasian group it was only reduced after the 4 mg dose and not 4 mg/70 kg, an 
unexpected finding as the mean weight-adjusted dose for the Caucasians was also 
4 mg. No effect was seen on supine SBP after either dose. The greater effect 
on standing blood pressure was probably mediated by postural hypotension. As 
angiotensin converting enzyme also inactivates bradykinin, inhibition of A C E leads 
to an accumulation of bradykinin which has vasodilatory properties (Hajj-ali & 
Zimmerman, 1985). Previous work has shown that vasoactive peptides may be 
involved in the postural hypotensive effect of ACE-inhibitors in anephric patients 
(Man in，t Veld, Wenting & Schalekamp, 1979). Supine diastolic blood pressure 
was significantly reduced in Caucasians after the weight-adjusted dose, but not 
after the 4 mg dose. Chinese supine DBP was not affected. In the standing 
position, both groups showed a reduction in DBP regardless of dose. It is 
interesting to note that the effect of ACE-inhibition on DBP in the Caucasian 
subjects appeared to be greater and of a longer duration than the effects in the 
Chinese. Supine heart rate showed a significant decrease at 4 and 8 hours in the 
Caucasian subjects and a significant increase at 12 and 24 hours in the Chinese 
after the 4 mg dose. However, standing heart rate was not significantly changed 
in either group. This effect was absent when 4 mg/70 kg was given. Some 
studies have reported a lack of any effect on heart rate as a result of ACE-
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inhibition. This has been attributed to down-regulation of baroreflexes, meaning 
that baroreceptors respond less well to incoming signals (Giudicelli, Richer, 
Richard & Thuillez, 1991). Such an effect on the baroreceptors would decrease 
parasympathetic tone and might explain why tachycardia is usually not induced by 
the peripheral vasodilitatory effects of ACE-inhibition (Opie, 1992, p 12). 
However, Lees et al (1988) demonstrate a significant rise in heart rate in 
normotensive volunteers after 8 mg of perindopril. and in another study, also with 
4 mg of perindopril (Lees & Reid，1987). The reduction in heart rate in 
Caucasian subjects is difficult to explain. It must be remembered that as there was 
no placebo control group in this study, the effects of diumal changes on blood 
pressure and heart rate cannot be determined, heart rate is usually higher in the 
evening in healthy individuals and blood pressure has been shown to decline in 
some studies (see Aschoff, 1992). 
Interpretation of the results generated by the non-invasive haemodynamic 
monitoring is complicated by several factors. Firstly, the small number of subjects 
in each ethnic group, which was really insufficient to make any valid statistical 
comparison for racial differences. In addition, although all four of the Chinese 
subjects were monitored for the full 8 hour period, only four of the five Caucasian 
subjects were monitored at 6 hours and only two at 8 hours. As the Caucasian 
data at 8 hours only represents 2 subjects, it cannot be considered as 
representative. 
Secondly the male to female ratio, was 1:3 in the Chinese group and 4:1 
in the Caucasian group. Certain haemodynamic parameters such as TFI are sex 
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related and therefore the differences observed between groups in some instances 
could be attributed to sex rather than ethnic background. 
Thirdly, as the subjects were monitored over 8 hours after a 10 hour fast, 
they all consumed a light meal between 3 and 4 hours post-dose and this could 
well have effected the results of the monitoring. C. de Mey et al (1989) used 
transthoracic impedance cardiography to assess postprandial haemodynamic 
changes following a standard 3100 kjoule cold meal in 12 supine fasting men, and 
made the following observations. Eating causes a swift and brief increase in SBP 
and stroke volume and a rapid and lasting decrease in DBP and M B P and SVRI 
with a corresponding increase in HR. It also causes an increase in CO, partly 
mediated by the increase in HR. They concluded that eating has predominantly 
vascular effects but also direct cardiac effects. 
Finally, the possibility of diumal changes in haemodynamics cannot be 
ignored. However, the combined data of 9 subjects is sufficient to examine the 
haemodynamic effects of the drug. 
Although changes were observed in most parameters after the 
administration of perindopril, the only change that reached statistical significance 
was in the SVRI. SVRI is a function of M B P and CI and is calculated as:-
M B P X 80 
CI 
Therefore one might expect an accompanying decrease in either M B P or rise in 
CI, or both. There was a slight decrease in MBP, maximal at 6 hours both supine 
and standing, however it did not approach significance. A sharp rise in CI was 
noted, starting at 2 hours post-dose and reaching its peak at 4 hours, again it did 
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not approach statistical significance but it seems likely that this was responsible for 
the drop in SVRI. Thuillez et al (1990) demonstrated a rise in CI (12%) and a 
decrease in SVRI (18%) in patients with congestive heart failure given a single 
oral dose of perindopril 4 mg, following cardiac catheterisation. The patients were 
salt restricted but diuretic therapy had been stopped. These changes were also 
maximal at 4 hours post-dose. Such effects have been noted in other studies on 
patients with congestive heart failure (Levine et al.，1980; Kjekshus et al，1984) 
however, no information is available on CI and SVRI changes in healthy 
volunteers, at the time of writing. Although the intake of food between 3 and 4 
hours could have been responsible for the rise in CI and drop in SVRI in our 
subjects, it is interesting to note that the trend developed before the food was 
ingested, although the magnitude of the changes at 4 hour was probably due to the 
combined effect of perindopril and postprandial haemodynamic changes. It is also 
noteworthy that, in the subjects who were monitored, maximal plasma 
perindoprilat concentrations following a 4 mg dose of perindopril were reached at 
4 hours in Chinese subjects and 7.2 hours in the Caucasians. Maximum ACE-
inhibition was reached in the Chinese before the Caucasians (4.5 ±1.0 hours vs. 
6.0 ± 1.4 hours). This might explain the sudden sharp rise in CI, but not why 
the rise should be more marked in the Caucasian subjects at 4 hours. It is also 
somewhat surprising that the response in Caucasians is more marked at 4 hours, 
as peak plasma perindoprilat concentrations were reached in the Chinese subjects 
before the Caucasians. This could in fact be a more marked response to their 
meal, rather than a response to the drug itself. The large standard deviation of the 
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changes in SI and VETI makes it hard to draw any conclusion from the data. 
There was a difference in the mean TFI of both groups but this was 
undoubtably due to the sex distribution. The normal range of TFI is 27 - 48 ohm 
in females and 20-33 ohm in males (in the supine position). The TFI is higher in 
the Chinese, predominantly female group. VETI was similar in both groups. 
Other studies involving healthy volunteers have noted little or no effect on blood 
pressure in healthy subjects (Lees & Reid，1987). By the nature of its dilatatory 
effect on large blood vessels, even after acute administration, perindopril is 
generally expected to effect systolic blood pressure more than diastolic blood 
pressure. The small reductions observed in this study are in line with those 
reported elsewhere. The greater reduction in DBP may partly be due to the fact 
that in healthy volunteers, whose blood pressure is not compromised by reduced 
arterial compliance, improvement of such may have little effect on systolic blood 
pressure. The rise in mean HR, reflected in both supine and standing data, started 
at 3 hours prior to the ingestion of food. However, the sharp rise between 3 and 
4 hours was most likely to be due to a postprandial effect. An absence of any 
significant effect of perindopril administration on heart rate has been noted in other 
studies involving healthy volunteers and therefore it seems unlikely that this 
pattern was an effect of the drug (Waeber, Nussberger, Perret, Santoni & Brunner， 
1989). 
As previously mentioned, any racial interpretation of the data has several 
limitations. It would appear that the haemodynamic response is similar in both 
Chinese and Caucasians. The pharmacokinetics of perindopril do appear to be 
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marginally altered in Chinese, i.e. perindopril t ^ is reached significantly shorter 
in the Chinese subjects. However, this difference does not appear to affect the 
haemodynamics in Chinese. The antihypertensive efficacy of perindopril appears 
to be dependent on the percentage of ACE-inhibition and that it obviously 
dependant on the dose administered (Lees & Reid，1985). 
In all the data accumulated during the course of this study, no evidence was 
found to suggest any clinically relevant ethnic difference in the pharmacokinetics 
or the pharmacodynamics of perindopril in Chinese and Caucasians. Perindopril 
was well tolerated in both racial groups with no adverse-effects being directly 
attributable to the drug. It is therefore reasonable to conclude that no adjustment 
of the standard 4 mg dose is necessary in Chinese patients. 
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The Cilazapril Study 
4,1 INTRODUCTION 
Like perindopril, cilazapril was also developed in the West and tested in 
a predominantly Caucasian population. Interest in its pharmacokinetics in Asian 
populations was peaked when it was noticed that the dose-response curve for 
cilazapril was different in Japanese patients with essential hypertension (personal 
communication from Michael Egan, Regional Product Manager, Roche 
Pharmaceuticals and Chemical Ltd). As is often the case, no direct comparison 
of the pharmacokinetics had been made between Asians and Caucasians when our 
study was designed. 
4.1.1 Aims 
The aim of the study was to investigate the pharmacokinetics of cilazapril 
and cilazaprilat in healthy, normotensive, Chinese and Caucasian volunteers. 
However, ultimately it was only possible to study cilazaprilat in plasma. The 
kinetics would be studied after a standard 2.5 mg dose of cilazapril. 
The endocrine effects would be studied by measurement ACE-Activity, 
ACE-inhibition, plasma renin-activity (PRA) and aldosterone. The 
haemodynamics were evaluated by measurement of blood pressure heart rate and 
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transthoracic electrical bioimpedance. 
4.2 METHODOLOGY 
4.2.1 Inclusion Criteria 
• All subjects must be between 18-50 years of age 
• Body weight within 土 15% of their ideal weight (Metropolitan Life 
Insurance Charts, 1983) 
• Written informed consent must be obtained 
• Subjects should be free of any disease or altered physiological condition as 
evidenced by medical history, physical and laboratory examination 
• The medical examination must be performed within 14 days of the start of 
the study 
4.2.2, Exclusion Criteria 
• Screening data outside of normal limits and being of clinical relevance on 
physical examination or laboratory tests 
參 Supine blood pressure > 150/90 m m H g 
• History of cardiovascular, hepatic, renal (creatinine clearance < 80 
ml/min), respiratory, gastrointestinal, endocrine, metabolic, or mental 
disease 
• Smoking more than 10 cigarettes a day 
• History or concomitant diagnosis of substance abuse (alcohol or drugs) 
• Intake of an experimental drug within 30 days prior to the commencement 
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of the study 
• Participation in a clinical trial in the past 3 months 
• Intake of drugs which may affect blood pressure or which are known to 
interact with, blunt or potentiate the effects of ACE-inhibitors, e.g.: 
- antihypertensives (vasodilators, ACE-inhibitors other than the trial 
drug, diuretics, calcium antagonists, B-blockers) 
- sympathomimetic agents 
- aminophylline or analogues 
- MAO-inhibitors 
- anticonvulsant drugs 
• Women of childbearing potential in whom the possibility of pregnancy 
cannot be excluded 
• Subjects unable to understand instructions 
• Subjects unable or unwilling to provide informed consent 
4.2.3 Study Design 
The study was performed in accordance with the revised Declaration of 
Helsinki (1983) governing experimentation with human volunteers. Subjects gave 
their written informed consent before being included. 
W e studied 12 Chinese and 13 Caucasian, healthy normotensive volunteers. 
The male to female ratio was 6:6 in the Chinese group and 7:6 in the Caucasian 
group. The comparative height, weight and age of the two study populations are 
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shown in table 4.1. 
Table 4.1: Characteristics of the study population (mean 土 SD plus the range). 
Race n M:F Age (yr) Weight (kg) Height (cm) 
Chinese 12 6:6 24 士 3.1 56.3 土 7.4 164 土 8.3 
(21 - 32) (47 - 69) (154 - 179) 
Caucasians 13 7:6 31 士 7.3 67.8 土 14.3 174 士 8.5 
(23 - 44) (50 - 99) (161 - 190) 
Prior to selection all volunteers underwent a thorough medical examination. 
This included a general physical examination, a complete medical history, an 
electrocardiogram (ECG), and blood pressure (BP) and heart rate (HR) 
measurement after the subject had been seated for 5 minutes. Blood was taken for 
a variety of haematological and biochemical investigations and urine was taken for 
dip-stick analysis: 
眷 Haematology: haemoglobin, haematocrit, erythrocytes, leukocytes with 
differential count, thrombocytes and prothrombin time 
• Biochemistry: glucose, urea, serum creatinine, triglycerides, cholesterol, 
total protein, albumin, total serum bilirubin, alkaline phosphatase, ASAT 
(GOT), A L A T (GPT), 7GT, sodium, potassium and calcium 
• Urine: pH, protein, glucose, sediment 
Blood was also taken for baseline determinations of ACE, plasma renin-activity 
and aldosterone. 
Those subjects who met the inclusion criteria started the study within 14 
days, if the study was delayed for any reason, the full medical was repeated again. 
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A post-study evaluation was also conducted, for which all the above investigations 
were repeated again. 
A single oral dose of cilazapril 2.5 mg in the form of a single capsule was 
administered with 150 ml of water. A standard light lunch was served after a 
delay of at least 4 hours post-dosing. The evening meal was also light. Subjects 
stayed in CPSU until their cannula was removed after the 12 hour sample and 
returned the next morning to give a blood sample, collect a new urine bottle and 
have their supine BP and H R measured. This routine continued until 72 hours 
post-dose. The subjects then returned within 7 days for their post-study medical 
evaluation. 
4.2.4 Blood Sampling 
Blood was taken for plasma cilazaprilat, ACE-activity, PRA and 
aldosterone. Blood sampling was at 0，0.5, 1，1.5, 2，3，4，6，8，12, 24, 48，and 
72 hours for cilazaprilat concentrations and ACE-activity. Sampling for PRA and 
aldosterone was at 0，2, 4，6，8，24, 48 and 72 hours. E D T A tubes for hormone 
samples were chilled in ice prior to sample collection, and all blood samples were 
placed in crushed ice immediately after collection. The samples were then 
centrifuged within 15 minutes in a refrigerated centrifuge set at 4°C and 3000 rpm. 
The plasma for drug concentrations was stored at -20°C prior to analysis. Plasma 
for hormone determinations was stored at -70。C. 
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4.2.5 Urine Sampling 
Urine was collected over the following time periods: predose, 0-4，4-8，8-
12，12-24, and 24-48 hours after drug administration. After each collection, the 
pH and the total volume of the urine was measured and recorded and a 10 ml 
aliquot was taken after mixing to ensure homogeneity. The samples were then 
frozen at -20°C prior to analysis. No additive was put in the collection bottles, 
however, the bottles were stored in the fridge whilst the subjects were in CPSU 
and they were asked to keep the bottles refrigerated when not in the clinic. To 
ensure an adequate collection of urine in the initial study period, the subjects were 
asked to drink at least 100 ml of water every two hours. 
4.2.6 Blood Pressure and Heart Rate 
BP and H R were measured 15 minutes prior to dosing and at 1.5, 2, 3, 4， 
5，6，8，10，12，24, 48 and 72 hours, when the subject had been lying in the 
supine position for 5 minutes. All recordings were made with the Datascope 
Accutor automatic sphygmomanometer. 
4.2.7 Non-Invasive Haemodynamic Monitoring 
All the subjects that took part in the pharmacokinetic study also consented 
to non-invasive haemodynamic monitoring. However, the data for one Caucasian 
subject and one Chinese subject were unusuable, making the final numbers 11 
Chinese and 12 Caucasians. The non-invasive haemodynamic monitoring was 
performed prior to dosing and between and 4 hours post-dose, before the subjects 
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ate. Subjects were monitored in either slow mode (the mean of 15 consecutive 
beats) or fast mode (beat-to beat recording) for a total of 34 minutes at each 
session under the following schedule: 
Supine - Standing 
0 Start 5 minutes supine rest 
+ 5 Record in slow mode for 3 minutes 
+ 8 Fast mode for 1 minute 
+ 9 Subject stands, fast mode continued for 2 minutes 
+ 11 Slow mode for 3 minutes 
Deep Breathing 
+15 Subject starts deep breathing (6 breaths/min for 2 minutes), record 
in fast mode 
+ 17 Subject stops deep breathing, switch to slow mode for 1 minute 
Valsalva Manoeuvres 
+ 18 Record in fast mode for 1 minute 
+ 19 Start strain (40 m m H g for 15 seconds). Start BP recordings 
immediately after the strain 
+21 Switch to slow mode for one minute 
+22 Record in fast mode for 1 minute 
+23 Start strain (40 m m H g for 15 seconds). Start BP recordings 
immediately after the strain 
+25 Switch to slow mode for 1 minute 
+26 Record fast mode 1 minute 
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+27 Start strain (40 m m H g for 15 seconds). Start BP recordings 
immediately after the strain 
+29 Switch to slow mode for one minute 
Handgrip 
+30 Record in fast mode 
+31 Start handgrip (30% of maximum for 2 minutes) 
+33 Stop handgrip. Continue fast mode recording for 1 minute 
+34 End 
BP and H R were also measured throughout the monitoring sessions at one 
minute intervals, again using the Datascope Accutor. This added SBP, DBP, M B P 
and H R to the haemodynamic monitoring data. 
4.2.8 Analysis of Plasma Cilazaprilat Samples 
The assay was performed by F. Hoffmann-La Roche Ltd. at their 
laboratories in Basel, Switzerland. Unfortunately, the head of the team in charge 
of assaying the samples for Roche, Dr. R. Ambros, refused to have the samples 
assayed for cilazapril, once the results for cilazaprilat were known. He also 
refused to allow any analysis of urine samples. Despite vehement protests by my 
Supervisor, Dr. Critchley, the data was still withheld. Consequently, no data was 
available on concentrations of the prodrug. 
Determination of cilazaprilat in plasma was by radioimmunoassay (RIA). 
The samples were heat-treated to inactivate endogenous ACE, then incubated with 
rabbit-lung A C E in the prescence of the artificial substrate [14c]-Hip.His.Leu (Ro 
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31-3162/001). Liberated [14c]-hippuric acid was extracted with pentyl acetate, 
and radioactivity determined by liquid scintillation counting. Standards and quality 
control samples were processed along with the unknowns and a calibration curve 
was calculated for each analytical batch being linear from 0.165-676 /xg/1 over 
three ranging studies. The limit of detection was set by the lowest standard at 
0.165 pg/1. All components which inhibit A C E were detected, the parent drug, 
cilazapril is not an ACE-inhibitor. 
4.2,9 Hormone and Enzyme Assays 
These assays were also performed by F. Hoffmann-La Roche Ltd. 
Angiotensin I was not measured, despite being included in the protocol. Again, 
this was due to a unilateral decision by Dr. Ambros. ACE-activity was 
determined using a radio-immunoassay. The samples were incubated directly with 
the artificial substrate and the assay was performed without standards. The limit 
of quantification was approximately 0.005 U/1, where one unit represents one 
micromole of radioactive substrate hydrolysed per minute. 
Aldosterone was also measured using a radioimmunoassay technique, with 
^^ I^-aldosterone. The limit of quantification was 15 pg/ml. 
PRA calculated with methods equivalent to those described in the General 
Methodology, section 2.6.2 
4,3 DATA ANALYSIS AND STATISTICAL METHODS 
4.3.1 Pharmacokinetic Analysis 
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The individual plasma cilazaprilat versus time curves were fitted to a 
triexponential model with first order absorption, using the SIPHAR 
pharmacokinetic modeling programme (see General Methodology, section 2.6.1). 
4.3.2 Pharmacodynamic Analysis of Hormone Data 
A full description of the calculation of ACE-inhibition, and can 
be found in the General Methodology, section 2.6.2). 
43.3 Analysis of Non-Invasive Haemodynamic Monitoring Data 
The data generated by the non-invasive haemodynamic monitoring was 
initially stored in an ASCII format file and then imported into Quattro Pro 
(Version 4.0; Borland, 1992) for analysis (see Figure 2.6). The mean of the 
following data sets was taken for every subject: 
• 3 minutes steady-state in the supine position (slow mode) 
• 3 minutes steady-state in the standing position (slow mode) 
• 1 minute steady-state H R in the supine position (fast mode) 
• 1 minute steady-state H R in the standing position (fast mode) 
• Maximum and minumum H R for each minute of deep breathing 
(fast mode). The percentage change was also calculated 
• Maximum HR, minimum HR, systolic overshoot and the Valsalva 
ratio of each Valsalva manoeuvre (fast mode) 
• 3 minutes steady-state supine SBP, DBP, M B P and H R 
• 3 minutes steady-state standing SBP, DBP, M B P and H R 
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• 3 minutes steady-state supine SVRI 
• 3 minutes steady-state standing SVRI 
The above means were then combined and analysed as Chinese vs. 
Caucasians. In addition, the data obtained from this study was compared with the 
data obtained from another study investigating the single dose pharmacokinetics 
of paracetamol. The paracetamol study was performed around the same time, 
using many of the same subjects as it was also designed for pharmacokinetic 
comparisons between ethnic groups. As paracetamol has no known effects on 
haemodynamics, it was decided to perform an identical protocol for TEB 
cardiography on these subjects and use the data as a control for the cilazapril 
study. The idea was that this would reveal the normal, diurnal fluctuations in 
haemodynamic parameters which were not due to ACE-inhibition and allow for 
any effects of blood sampling. Therefore, the results of those subjects who did 
both studies were compared for differences. Table 4.2 gives details of the subjects 
whose data could be directly compared. 
Table 4.2: The characteristics of those subjects who participated in both the 
cilazapril study and the paracetamol study. 
Race n M:F Age (yr) Weight (kg) Height (cm) 
Chinese 11 6:5 24 土 3.0 56.2 土 8.3 164 士 8.6 
Caucasians 9 6:3 29 士 7.7 68.0 土 12.7 175 士 7.8 
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4,3.4 Statistical Analysis 
Section 2.7 in General Methodology gives details of the statistical analysis 
used. However, the values for PRA and aldosterone could not be put through the 
standard analysis as many of the values lay outside the detection limits of the 
assays used. This meant that these values could only be analysed using non-
parametric methods. Therefore, PRA and aldosterone were compared between 
Chinese and Caucasians using the Mann-Whitney U Test and intra-group changes 
from baseline were compared using the Wilcoxon Matched Pairs Rank Test. 
4.4 PHARMACOKINETIC RESULTS 
4.4.1 Pharmacokinetics of Cilazaprilat in Plasma 
Mean plasma concentrations v>y. time are shown in Figure 4.1. The mean 
pharmacokinetic parameters for Chinese and Caucasians are listed in Tables 4.4 
and 4.5. 
The pharmacokinetics of cilazaprilat can be divided into three distinct 
phases, an initial phase of conversion from the prodrug, cilazapril, (t,^  36 土 0.07 
minutes in Chinese and 37 士 0.06 minutes in Caucasians), a distribution and 
elimination phase (t,^  1.9 士 0.12 hours in Chinese and 2.1 士 0.16 hours in 
Caucasians) and a prolonged, pure elimination phase (t,么 43.3 土 5 hours in 
Chinese and 49.5 ±6.8 hours in Caucasians). The absorption phase is short with 
C麵 occuring in under 2.5 hours in both groups. The prolonged elimination phase 
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Hg仏re 4.1： Mean plasma concentration v^ . time curves for cilazaprilat in 
Chinese and Caucasians after a single oral dose of cilazapril 2.5 mg. 
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is characterised by extremely low plasma concentrations of the drug representing 
4.5 土 0.8% and 3.4 士 0.4% of C應 in Chinese and Caucasians respectively at 
24 hours. By 72 hours the plasma concentrations represented 1.4 士 0.3% of C腿 
in Chinese and 0.2 ± 0.1% in Caucasians. 
The pharmacokinetics of cilazaprilat are very similar between the races. 
No statistical difference could be found between the groups at any of the time 
points measured. The only discemable difference in the pharmacokinetic 
parameters was in plasma clearance, which was significantly faster in the Chinese 
group (0.27 士 0.03 0.19 士 0.01 in Caucasians, p < 0.05). 
4.5 PHARMACODYNAMIC RESULTS 
4.5.1 Angiotensin Converting Enzyme Inhibition 
Figure 4.2 shows a plot of ACE-inhibition and ACE-activity against time. 
Tables 4.5 and 4.6 give the mean values for the pharmacodynamic parameters in 
Chinese and Caucasians. Figure 4.3 shows ACE-inhibition plotted against plasma 
cilazaprilat concentrations. Cilazaprilat is a potent inhibitor of A C E in the dosage 
administered. In both Chinese and Caucasians, a level of inhibition of nearly 
100% was reached within 2 hours. When ACE-inhibition and plasma cilazaprilat 
concentration are plotted together, it can be seen that concentrations as low as 5 
/xg/1 are sufficient to induce over 80% ACE-inhibition. 
No ethnic difference was seen in either the reduction in ACE-activity or the 
percentage of ACE-inhibition. ACE-activity was significantly reduced (p>0.01) 

































































































































































































































_re 4.3: Mean ACE-inhibition plotted against mean plasma cilazaprilat 
concentrations in Chinese and Caucasians after a single oral dose of cilazapril 2 5 
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Table 4.5: Pharmacodynamic parameters (ACE-inhibition) in Chinese subjects 
after administration of cilazapril 2.5 mg (* indicates that tl^ is given as the mean, 
minumum and maximum values). 
I I I ii 
隱 
Subjects I I以 
j W (h) (%) 
I I 
2 1 97.8 3.0 58.2 
3 1 98.0 2.0 60.9 
6 ！ 98.7 1.5 72.9 
7 ！ 99.0 2.0 71.9 
8 ！ 99.1 2.0 96.2 
9 ！ 98.8 1.5 72.3 
10 ！ 98.8 2.0 74.9 
11 ！ 97.2 1.5 73.2 
12 ！ 98.8 3.0 72.4 
14 ！ 97.6 3.0 72.5 
15 ！ 98.7 3.0 75.5 
16 ！ 98.8 1.5 72.6 
I I I 
1 
I 
Mean: ！ 98.4 2.0* 72.8 
SD: I 0.6 1.5* 9.1 
SEM: j 0.2 3.0' 2.6 
I I 
I I I I 
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Table 4.6: Pharmacodynamic parameters (ACE-inhibition) in Caucasian subjects 
after administration of cilazapril 2.5 mg (* indicates that tl^ is given as the mean, 
minumum and maximum values). 
j “"” = = = = = 
Subject i tl 匪 I以 
I m (%) (%) 
I “ n " 
I 
4 1 99.3 1.5 69.0 
5 j 99.0 1.5 72.6 
17 ； 98.5 1.5 69.6 
18 I 98.3 1.5 70.3 
19 ！ 98.2 1.5 75.3 
20 I 98.3 2.0 71.1 
21 ！ 97.8 2.0 57.4 
22 ！ 99.1 2.0 73.7 
23 I 97.8 2.0 72.5 
24 I 97.5 2.0 70.3 
25 ！ 97.8 3.0 74.9 
26 ！ 98.9 3.0 73.6 
27 I 98.7 3.0 79.3 睡 I 1 
I 
Mean: ! 98.4 2.0_ 71.5 
SD: j 0.6 1.5* 5.1 
SEM: I 0.2 3.0' 1.4 
I I • I I I 
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4丄2 Aldosterone and Plasma Renin Activity (PRA) 
Figure 4.4 shows mean values for PRA in both Chinese and Caucasians. 
Graphic representation of the aldosterone data was not possible due to the large 
number of values which lay below the limit of detection of the assay. From 2 
hours post-dose the majority of values in Caucasian subjects were below 30 pg/ml 
and many values in the Chinese data were also extremely low. The Mann-
Whitney U test revealed that aldosterone concentrations at 48 hours were 
significantly higher in the Chinese group than in the Caucasians (p <0.05). 
Despite a trend towards higher values in the Chinese group, this was the only time 
point which reached statistical significance. Aldosterone was reduced in the 
Chinese subjects until 8 hours post-dose, however when the p value was corrected 
for the number of comparisons, the significance was lost. There was also a 
tendency towards lower values up until 8 hours in the Caucasian group. 
PRA rose significantly in both Chinese and Caucasians. However, the rise was 
significantly more marked in Chinese, especially at 4 hours (p <0.05). It reached 
a peak at 6 hours in both groups and had returned to its baseline values by 72 
hours. 
4.5.3 Blood Pressure and Heart Rate 
Mean systolic blood pressure (SBP) diastolic blood pressure (DBP) and 
heart rate (HR) are shown in Figure 4.5. A one-way repeated measures analysis 
of variance showed that the difference in the mean values within each group was 
greater than would be expected by chance (p < 0.01 for SBP in both races and for 
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风g聰 4*4: Mean plasma renin activity (PRA) in Chinese and Caucasians after 
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Chinese HR, p <0.05 for DBP in both races and for H R in Caucasians). 
SBP was reduced in Chinese at 4 hours (p <0.05) and 5 hours (p 
>0.001)，whereupon it rose to above baseline levels. In Caucasians, SBP was 
significantly reduced at 6 hours (p <0.05) and had not quite returned to the 
baseline value at 72 hours. 
D B P was not significantly reduced in Chinese, after allowance for multiple 
comparisons had been made (prior to correction, DBP was reduced at 5 hours, p 
<0.05). In fact, between 4 and 10 hours it showed a tendency to rise, becoming 
significantly higher than the Caucasian values at 10 hours (p <0.05). The profile 
of the Caucasian means was slightly different, with DBP being significantly 
reduced at 3，6，and 48 hours post dose (p <0.05) and a trend towards lower 
values remaining at 72 hours. 
H R seemed to rise in the Chinese group from 4 hours onwards. This 
increase was significant before correction at 6，8，10 and 72 hours. However, 
after correction it was only significant at 72 hours (p < 0.001). It was 
significantly higher than Caucasian values at all time points after 0 hours with the 
exceptions the of 5 and 12 hours points (p > 0.05). This difference was especially 
large at 6 (p <0.01), 24 (p <0.001) and 72 (p <0.01) hours. In Caucasians, H R 
was significantly reduced at both the 1.5 (p <0.05) and 2 (p >0.01) hour time 
points after correction for multiple comparisons. At 5 hours it had returned to the 
pre-dose value and thereafter no change was discemable. 
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4.5.4 Safety and Tolerance 
Cilazapril was quite well tolerated throughout the study in both Chinese and 
Caucasian subjects. However, there were some adverse effects reported. Table 
4.6 describes the nature and incidence of adverse-events in both racial groups. 
Table 4.7: The nature and incidence of adverse-events in Chinese and Caucasians 
following a single oral dose of cilazapril 2.5 mg. 
Adverse-effect Chinese Caucasians Remarks 
Headache f ^ 4 (3F/1M) 1 severe, 1 moderate & 2 
mild, lasting from 4-12 h 
Transient 1 (F) H f ) Both moderate, duration 20-40 
Hypotension min 
Facial Flushing "o 1 (F) Same individual who suffered~ 
a severe headache, lasted 12 
hours 
Nausea 1 (F) 0 Same individual who suffered 
hypotension & a moderate 
headache 
In total 5 Caucasians and 1 Chinese subject spontaneously reported 
symptoms consistent with the effects of the drug. The incidence of adverse-effects 
did appear to be higher in Caucasian individuals. One Chinese and one Caucasian 
had short periods of hypotension, during which the lowest blood pressure value 
was 60/27 m m H g in the Chinese subject and 78/42 m m H g the Caucasian. The BP 
of both subjects returned to normal when resting supine with the foot of the bed 
raised and required no further intervention. None of the above effects were 
considered to be serious or life-threatening. 
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4丄 5 Non-Invasive Haemodynamic Monitoring 
The mean data values in Chinese and Caucasians for blood pressure, heart 
rate and haemodynamic parameters are shown in Tables 4.7 and 4.10. 
Blood pressure was lowered significantly 4 hours after cilazapril dosing. 
There were no significant differences in the magnitude of these reductions between 
Chinese and Caucasians (see Figure 4.5). Figure 4.6 shows the difference 
between erect and supine values (erect value minus supine value) before and after 
cilazapril dosing in both Chinese and Caucasians. Figures 4.7 and 4.8 show the 
percentage change in supine and standing blood pressure in the same individual 
after a single dose of cilazapril 2.5 mg and after a weight-adjusted dose of 
paracetamol syrup (20 mg/kg). SBP was reduced at 4 hours in Chinese in both 
the supine and standing positions (supine 104 士 2.78 vs. 98.2 士 2.29，standing 
106 士 3.18 V5". 97.1 士 3.01，p >0.05). However, it was only reduced in the 
supine position in Caucasians (102 土 2.15 v^. 107 士 1.99，p <0.05). When 
erect minus supine values for SBP were compared for before and after treatment 
with cilazapril, the reponse to standing appeared to be abolished in Chinese 
subjects (Figure 4.6). Before cilazapril administration, systolic blood pressure 
rose by a mean 4.3 士 1.7 m m H g when the subjects had been standing for 3 
minutes, however 4 hours after administration of cilazapril, erect minus supine 
values were -0.6 士 1.3 m m H g , a statistically significant difference from the pre-
dose value (p <0.05). This effect was not seen in the Caucasian subjects, and so 
there was also a significant difference between the racial groups (p <0.01). 
When the percentage change in supine and standing systolic blood pressure values 
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after cilazapril administration were compared with those recorded after 
paracetamol administration, there was a tendency towards lower values 4 hours 
after cilazapril in both Chinese and Caucasians. However, the difference only 
reaches significance in the standing position in Chinese (-8.96 土 1.41 v^. -2.54 
士 0.79，p <0.05) and in the supine position in Caucasians (-5.50 士 1.56 v«s. 0.34 
士 1.75，p <0.05) post cilazapril and paracetamol respectively. 
D B P was also reduced at 4 hours compared to pre-dose in Chinese 
subjects, regardless of position (supine 58.1 土 1.72 v^. 62.2 ±1.88 m m H g , 
standing 62.5 士 2.82 V5. 69.8 土 2.31 m m H g , p <0.05). Caucasians also 
showed a significant reduction (supine 63.8 士 0.94 v又 59.1 士 1.30，standing 
73.3 士 1.86 67.8 土 2.26，p <0.05). The change in DBP on standing was 
not significantly altered by administration of cilazapril, although values did tend 
to be marginally higher post-dose. No statistical difference was noted between 
D B P post-paracetamol administration and DBP post-cilazapril administration in 
Chinese subjects although values after both treatments did seem to increase on 
standing. D B P in Caucasians was significantly lower in Caucasians after cilazapril 
administration in both the supine (-8.18 士 1.34 -0.09 士 2.22) and standing 
(-9.19 土 3.17 v^. -0.97 土 1.34) positions. 
M B P was reduced compared to pre-dose in Chinese both supine and 
standing (supine 79.5 土 2.03 V5. 76.6 土 2.10，standing 86.6 士 2.78 v^. 80.4 土 
2.98，p <0.05) but only in the supine position in Caucasians (82.0 士 1.40 v^. 
77.9 士 1.62，p <0.05). No effect on the response to standing was discemable 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































，re 4 6: Mean supine and standing systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and mean blood pressure (MBP) in Chinese (n=ll) and 
Caucasians (n=12) pre-dose and 4 hours post a single, oral dose of cilazapril 2.5 
mg (*= p <0.05 v^. pre-dose values). 
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a significant difference between the change in supine M B P post-cilazapril and post-
paracetamol in Chinese subjects (-3.68 士 1.12% v^ . -0.94 士 1.90%，for cilazapril 
and paracetamol respectively, p <0.05). 
H R in the supine position was not altered in Chinese 4 hours post-cilazapril 
compared to pre-dose (Figure 4.10). However, standing H R had risen ( 88.2 士 
4.01 82.5 士 3.54, p <0.05). In Caucasians, there was a slight but significant 
decrease in supine H R values (57.3 士 1.63 v义 62.1 士 1.86，p <0.05). Figure 
4.11 shows the effect of cilazapril on H R in response to standing. A significant 
increase was seen in both Chinese (23.7 士 2.79 bpm v^ . 17.0 士 2.58 bpm, p 
<0.05) and Caucasian (19.8 士 1.50 V5. 12.6 士 1.52，p <0.05) subjects. In 
Chinese subjects, the mean percentage change from pre-treatment values for supine 
H R 4 hours post-cilazapril and 4 hours post-paracetamol were nearly identical and 
both were significantly different from the Caucasian values at that time (post-
cilazapril -1.53 士 1.35% v^ . -7.65 士 1.25%，p <0.05; post-paracetamol 1.51 
士 1.72% vs, -8.50 士 2.39%，p <0.05, in Chinese and Caucasians respectively), 
see Figure 4.12. In the standing position, an increase in H R was seen in Chinese 
in comparison to the post-paracetamol value (7.17 士 2.70% v^ . -2.25 土 2.69%， 
p <0.05). Although the same pattern was evident in Caucasians, it did not reach 
statistical significance (see Figure 4.13). 
Thoracic fluid index (TFI) differed little between the groups and was not 
significantly affected by cilazapril administration at the times measured. 
Stroke index (SI) was also unaffected by cilazapril administration at 4 hours 
post-dose. Erect minus supine values pre and post-dose were very similar in both 
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Chapter 4 - The Cilazapnl Study 176 
Chinese and Caucasians (see Figure 4.11). A comparison of post-paracetamol 
with post-cilazapril values shows little difference in the supine position, either 
between treatments or between doses (see Figure 4.12). However, in the standing 
position, there appears to be a trend towards a rise in SI at 4 hours in Chinese, 
regardless of drug administered, and a fall in Caucasians, less so after cilazapril. 
Although these trends were not statistically significant. 
Supine cardiac index (CI) showed little change 4 hours post-cilazapril. 
However, in the standing position it was significantly raised at 4 hours in the 
Chinese group (3.55 土 0.64 3.20 土 0.16，p <0.05), see Figure 4.10. 
Caucasian values showed no significant trend. Figure 4.14 shows the effect of 
cilazapril on CI in response to standing. A significant reduction in the fall in CI 
on standing is seen in both Chinese and Caucasians in comparison with pre-dose 
(Chinese -0.53 士 0.14 -0.91 ± 0.14 1 rnin-^m^, p <0.05; Caucasians -0.40 
士 0.26 -0.74 士 0.23 1 min-^m^ p <0.05). A comparison with post-
paracetamol data (Figure 4.13) reveals a significant rise in standing CI in 
Caucasians when taken as a percentage change from its baseline value (3.70 士 
2.49% -10.57 士 3.50%，p <0.01; see Figure 4.13). This effect was not 
significant in the Chinese subjects (11.4 ±4.27% v义 6.06 士 6.13%). 
There was no significant change in systemic vascular resistance (SVRI) 
between pre and post-cilazapril mean values. Although in both groups cilazapril 
attenuated the rise in SVRI on standing (Chinese 358 士 98.6 vs. 665 土 125 dyn 
sec-^ cm-^ m'S p <0.05; Caucasians 293 土 181 V5. 497 土 167 dyn p 






























































































































































































































































































































































































































































































































































































Chapter 3 - The Perindopril Study 179 
were compared with the mean values post-paracetamol, a highly significant 
difference was seen in Caucasians whose standing values post-cilazapril fell, and 
rose post-paracetamol (-7.94 土 3.09% v^ . 12.7 土 6.46%，p <0.01)，see Figure 
4.16. 
The protocol included the handgrip as an isometric exercise, but no 
significant difference was found between the races. The results before cilazapril 
administration were similar to those obtained afterwards. Figure 4.17 shows the 
overshoot in SBP taken immediately after the 15 second Valsalva manouevre (the 
mean of 3 values was taken). The Valsalva ratio (the heart rate ratio) was not 
altered by cilazapril. No significant change was seen between races or treatments. 
However, the overshoot did appear to be slightly lower after treatment with 
cilazapril. There was a large degree of both inter and intra-subject deviation. 
Figure 4.18 gives the mean percentage change in blood pressure and heart 
rate after the subjects had maintained 30% of their maximum handgrip for a period 
of 2 minutes. The values both pre and post-cilazapril administration are 
comparable. No difference could be found either between Chinese and 
Caucasians, or between treatments (cilazapril v^ . paracetamol). 
Maximum and minimum H R during the 2 minutes of deep breathing were 
recorded and the difference between them expressed as a percentage of the steady 
state HR. Cilazapril had no effect on any of these values in either group. Values 
before and after cilazapril were virtually identical. 
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J^^re 4.17： The overshoot in systolic blood pressure after the Valsalva 
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4.6 Discussion 
The pharmacokinetics of cilazapril fitted quite well to a standard two-
compartment model with first-order absorption. The parameters obtained from 
this model are in line with those previously reported in the literature (see Table 
4.11). 
Tohle 4,12: A comparison between the pharmacokinetic parameters obtained for Chinese 
and Caucasians in this study and those published by Francis et al. (1990) after a 2.5 mg 
dose of cilazapril (* Clearance values were not weight-adjusted by Francis et al.). 
Investigator Cmax t^ t ^ AUCoo 
( _ (h) (h) (fig t】.h) (I kgV)* 
This study: 
Chinese 28±11 1.9 土 0.4 43 士 17 181 土 51 0.27 土 0.1 
Caucasians 28±12 2.1±0.2 50±24 214 土 56 0.19 士 0.1 
Francis et al. 36士 13 1.3土0.2 37士 11 250士60 0.29±0.1 
The pharmacokinetics of cilazapril are non-linear after repeated dosing, 
probably due to saturable binding of the active metabolite to A C E (Frances, 
Brown, Kler, d'Amore, Nussberger, Waeber & Brunner, 1987; Mulder & Szucs， 
1989; Szucs, 1991). Efforts have been made by Frances et al. (1990) to develop 
a mathematical model which better describes the pharmacokinetics after repeated 
administration and relates the plasma concentration to ACE-inhibition. The model 
they developed makes an excellent attempt to characterise a complicated 
physiological process, which is over-simplifed by a standard two-compartment 
model. However, the application of a complex "physiologically realistic" model 
did not seem warranted for a single dose study, as the pharmacokinetics in this 
instance are essentially linear. In addition, the method described by Francis et al 
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(1990) made no attempt to fit the absorption/conversion phase of the curve, and 
so ignores an important physiological process. 
From the data produced in this study it appears that the pharmacokinetics 
of cilazaprilat in Chinese and Caucasians are extremely similar. The only 
statistical difference that could be found between the groups was in plasma 
clearance (p <0.05). This value is weight-adjusted, but the dose is not. Plasma 
clearance is calculated as dose divided by AUC^o, the dose was standard and so 
the only varying component is the AUCoo. This tended to be higher in the 
Caucasian subjects (214 土 16 181 土 15) although not significantly so. A 
trend towards a longer is also seen, which must be a contributing factor. 
Values for tVia are variable even within the same subject, being highly dependent 
on the number of points chosen on a given phase, therefore it is unlikely that the 
higher plasma clearance in Chinese represents a true physiological difference in 
the metabolism of the drug. 
The plasma pharmacodynamics are also in line with the responses described 
in published data in Caucasians. A significant rise from baseline values was seen 
in PRA in both Chinese and Caucasians, becoming significantly higher in Chinese 
at 4 hours post-dose. Aldosterone levels fell significantly in both groups but more 
so in Caucasians, especially at 48 hours (p <0.05). These effects are a direct 
result of ACE-inhibition by cilazapril. The somewhat greater rise in PRA in 
Chinese may be due to the fact that the dose was not weight-adjusted. The 
Chinese were both smaller and lighter than their Caucasian counterparts. 
The effect of cilazapril on blood pressure and heart rate was greater in this 
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study than has previously been reported in healthy volunteers. Several studies 
have reported no statistically significant change in BP or H R measured for 72 
hours after drug administration (Fasanella d, Amore, Bussien, Nussberger, Waeber， 
Turini，Brunner, Kler & Francis，1987; Nussberger, Fasanella d'Amore, Porchet， 
Waeber，Brunner, Brunner, Kler, Brown & Francis, 1987). However, Nussberger 
et aL only measured BP once daily (early in the morning) over a period of 72 
hours. The significant changes in blood pressure from our results were short-lived 
and occured between 4 hours and 12 hours after drug administration, being lowest 
at 5 hours post-dose. Fansanella et al measured BP at 1, 2, 4，6，8，and 24 hours 
post-dose, but only in six subjects, perhaps not enough to see changes of small 
magnitude. Elliot et al (1989) studied 10 normotensive males and did find a 
significant decrease in both SBP and D B P becoming evident at 2 hours post-dose 
and reaching a trough at 6 hours post-dose. This is in good agreement with our 
findings. Elliot et al did not measure BP at 5 hours post-dose, had we not done 
so, we would also have seen the trough 6 hours. A slightly greater effect was 
seen in SBP in Chinese, perhaps due to a dose-effect. Conversely, a greater 
decrease in D B P was seen in the Caucasian subjects, which was markedly lower 
than the Chinese values at 12 hours post-dose (p< 0.05). It is also interesting to 
note that cilazapril completely abolished the rise in SBP on standing in Chinese 
subjects. 
The changes in H R are perhaps the most interesting result from the study. 
The Chinese showed a significant increase in HR, remaining highly significant at 
72 hours. On the other hand, the Caucasians showed a significant decrease in H R 
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at 1.5 and 2 hours post-dose. A lack of a significant increase in HR, even in 
conjunction with a fall in BP with ACEI therapy has been widely reported in the 
literature. In fact, the study by Elliot et al was designed in an attempt to explain 
the lack of reflex cardio-acceleration in response to the hypotensive activity of 
ACE-inhibititors. They also reported no corresponding increase in H R and 
suggest that it is a general property of ACE-inhibition, and may be related to the 
withdrawal of the vagolytic actions of angiotensin II. However, they propose that 
increased paramsypathetic tone, although a contributary factor, is not sufficient to 
account for this discrepancy. The data from our Caucasian subjects seems to fit 
well with the above theories. The data from the Chinese, seems to support a 
decrease in parasympathetic tone, rather than an increase. It is significantly 
different at almost every time point throughout the study. It did not correspond 
to a drop in blood pressure, remaining elevated even after BP had returned to its 
baseline levels. H R as measured by the NCCOM3-R7, as opposed to the 
Datascope Accutor, was also significantly decreased in Caucasians at 4 hours (p 
<0.05). No change was discemable in the Chinese at this time point. This is not 
surprising, as although Chinese H R differed significantly from the Caucasians 
throughout the study it was only statistically raised in comparison to baseline 
values at 72 hours post-dose (p <0.01). However, the increase which occured 
when H R was monitored through the entire study period was in evidence 4 hours 
post-dose. This variation in response to ACE-inhibition may represent a racial 
difference, and is worth further investigation. 
Supine SVRI was not altered by cilazapril in either group, but standing 
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S VRI was almost halved regardless of race. The fall in supine BP after cilazapril 
was associated with a reduction in CI rather than SVRI in some subjects. The fall 
in CI on standing tended to be less after treatment, and was associated with a 
greater H R response in both groups (p <0.001), rather than a compensatory 
change in SI. One possible explanation for this is sparing of venomotor tone when 
the control of resistance is attenuated by cilazapril. 
The Valsalva manouevre can be used as an demonstration of baroreflex 
function (Elliot et aL，1989). The systolic overshoot was not significantly 
different before and after cilazapril administration, neither did it differ between 
treatment with paracetamol and treatment with cilazapril. In addition, the response 
to standing (orthostatic stress) was not altered in Caucasian subjects after ACE-
inhibition. These results indicate that baroreceptor function is unchanged by ACE-
inhibition (Elliott, Ajayi & Reid, 1989). However, the response to standing was 
abolished by cilazapril in Chinese subjects, perhaps indicating a decline in 
baroreceptor function. Cilazapril also failed to alter certain indicators of efferent 
sympathetic activity, namely SBP and H R in response to the handgrip (isometric 
exercise) in both Chinese and Caucasians. 
Cilazapril was well tolerated throughout the study, although the incidence 
of headache does seem higher than has previously been reported. Four out of 
thirteen Caucasian subjects spontaneously complained of headache, an incidence 
of 31%. Drug company reports give the incidence of headache as around 4.5% 
(Mulder & Szucs, 1989). Only one Chinese subject complained of headache, 
making the overall incidence, 20%. The subjects were told the possible side-
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effects of cilazapril prior to enlisting in the study, however after they were given 
the drug, they were never directly asked if they had experienced any adverse-
effects. The occurance of hypotensive episodes in two out of 25 subjects subjects 
seems slightly more than would be expected in normal volunteers after a single, 
low dose. 
From the data accumulated in this study, it appears that the 
pharmacokinetics of cilazapril are essentially the same in healthy, normotensive 
Chinese and Caucasians. No alteration of the standard dosage for either safety or 
efficacy is necessary in Chinese. However, it does appear that there may be some 





There is no evidence to suggest that the therapeutic usage of ACE-
inhibitors should be any different in Chinese. However, when the results of both 
the perindopril and cilazapril studies are examined together, certain trends are 
common to both. Table 5.1 gives a summary of the statistically signifcant 
differences found in each study. It was unfortunate that all the samples for the 
cilazaparil study were not analysed in the manner stipulated in the protocol and 
therefore the data are not available to make a full comparison of the results of the 
two studies. The parameters derived from the impedance cardiography 
measurements are not really comparable, due to the small numbers in each ethnic 
group for the perindopril study and the differences in the protocols. 
An increased plasma clearance of the active metabolite in Chinese was 
found with the standard dosage formulation of both drugs when the dose was not 
adjusted for weight. This is most likely due to the fact that the clearance is 
weight-adjusted to litres per kilogram but the dose was not (i.e. dose/AUCoo is 
divided by the weight which is smaller in the Chinese, giving them an inherently 
higher value). This is further supported by the plasma clearance values not being 
different between the groups before weight-adjustment. Furthermore plasma 
clearance values for perindoprilat after the 4 mg/70 kg dose did not differ 
significantly between the groups. 
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，I它 5 h A summary of the statistically significant differences found between 
Lpnese and Caucasians after a single oral dose of either perindopril 4 ms or 
cilazapril 2.5 mg ^ 
^ Fermaoprtlae OU 纖prilat 
Parameter 
Wf* between groups Diff, between groups 
Longer in Caucasians None 
MRT Longer in Caucasians None 
CL Higher in Chinese Higher in Chinese 
P J ^ None* Greater in Chinese 
SBP None Greater reduction in Chinese 
DBP More prolonged reduction in More prolonged reduction in 
Caucasians Caucasians 
HR Increased in Chinese Increased in Chinese 
Decreased in Caucasians Decreased in Caucasians 
* There was a tendency towards higher PRA values, but this did not reach significance 
Table 5.2: The molecular weight and standard recommended dosage for both 
perindopril and cilazapril. 
Brug Mofecqlar Weight R卿mm饼彻d Dosayg衫 
Perindopril 368.5^ Initally 2 mg o.d.，usual range 4-8 mg^ 
Cilazapril 417.5^ Initially 1 mg o.d., usual range 2.5-5mg2 
i(Martindale the Extra Pharmacopoeia, 1989) 
^(British National Formulary (BNF), 1993) 
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The longer and M R T in the Caucasian subjects compared to Chinese 
after the 4 mg dose of perindopril was not seen after the weight-adjusted dose, nor 
was there any ethnic difference between these two parameters after cilazapril 2.5 
mg. The significance of the difference after 4 mg of perindopril is therefore 
questionable. 
Chinese subjects exhibited a shorter t ^ after 4 mg of perindopril than their 
Caucasian counterparts. Although this difference did not reach significance when 
the dose was adjusted for weight, the same tendency could still be seen in the 
Chinese subjects. It would seem that perindopril may be absorbed slightly faster 
in Chinese subjects, although it is hard to propose a reason for this disparity. As 
the plasma data for the prodrug cilazapril was witheld it was not possible to see 
if the same phenomenon was in evidence when another ACE-inhibitor was given. 
The comparatively higher PRA levels which were seen in Chinese subjects 
after cilazapril administration, were not found when perindopril was given. 
Although there was a tendency towards higher values, with 4 mg perindopril, any 
suggestion of a difference between Chinese and Caucasians disappeared when the 
perindopril dose was adjusted for weight. It would appear that this was also an 
effect of the larger mg/kg dosage in Chinese subject. On a weight-to-weight basis, 
Cilazapril is initially a more potent inhibitor of A C E than perindopril, see Table 
5.2. Levels of ACE-inhibition were higher for all subjects after cilazapril 
administration, despite the smaller mg/kg dose, see Table 5.3. This will of course 
mean that the expected effect of ACE-inhibition, i.e. decrease in blood pressure, 
a rise in PRA and a fall in aldosterone concentrations, should be more pronounced 
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after cilazapril administration. This does seem to be the case, mean peak PRA 
concentration in Chinese was over double that seen after perindopril 4 mg. 
Although the statistically higher PRA in Chinese subjects after cilazapril could be 
a dose-effect, it is interesting to note that the extent of ACE-inhibition was the 
same (see Table 5.3). Without having given a weight-adjusted dose of cilazapril 
it is not possible to make further conclusions and we are assuming that the assays 
used for ACE-inhibition，PRA and aldosterone concentrations were equivalent for 
the two drugs studies. 
Table 5.3: Maximum percentage of ACE-inhibition (I^) and time to reach 
maximum inhibition (tl^J in Chinese and Caucasians after a single oral dose of 
perindopril 4 mg or cilazapril 2.5 mg. 
PeriBdoprll 4 mg Cilazapril t.5 mg 
Subjects r^ 
LAX TL 匪 IMAX 辽 隨 
Chinese 88 士 1.5 5.8 (0.5-1.7) 98 土 0.2 2.0 (1.5-3.0) 
Caucasians 84 士 2.1 6.4 (0.5-1.6) 98 士 0.2 2.0 (1.5-3.0) 
SBP was reduced to a greater extent in Chinese, but again, this is might be 
attributable to the discrepancy in body weight between the groups. However, 
other studies have shown little relation between the dose of cilazapril and the 
antihypertensive effect, unless the increment is large (Fasanella d'Amore, Bussien, 
Nussberger, Waeber, Turini, Brunner, Kler & Francis, 1987; Frances, Brown, 
Kler, d'Amore, Nussberger, Waeber & Brunner, 1987). It was not seen after the 
4 mg dose of perindopril. The more prolonged reduction in DBP was seen after 
both perindopril administration and cilazapril administration. This cannot be 
related to dosage, as the Caucasians were both taller and heavier on average. The 
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mechanisms of blood pressure control are so complex that it is impossible to 
postulate a reason for the difference from the data available in this study. The 
increased H R in Chinese subjects after both ACE-inhibitors is an interesting 
phenomenon. Figure 5.1 shows the results for DBP and H R after both doses of 
perindopril and after cilazapril administration in supine Chinese and Caucasians. 
Such an increase could be mediated by an increase in sympathetic activity in 
respect to parasympathetic activity. The haemodynamic monitoring protocol was 
designed to examine changes in parasympathetic activity (HR variation with deep 
breathing, and the change in H R on standing) and sympathetic activity (increase 
in BP and H R after the handgrip). However, none of the above tests were 
significantly altered by cilazapril administration. The only significant change that 
could signal an ethnic difference in response was the abolition of the response to 
standing in SBP in Chinese. This response depends on the integrity of the 
baroreflex arc (Elliott et al., 1989). Elliott also found no change in healthy, 
normotensive Caucasians after administration of the drug. The abolition of the 
pressor response in Chinese, would seem to indicate some modulation of that 
function. The many facets of baroreceptor function, their location, and responses 
are complex. Speculation about the precise mechanism of this difference is 
beyond the scope of this thesis. 
Chan et al. (1993) have reported that enalapril is less effective in Chinese 
diabetics with hypertension. Internal documents from Roche Nippon, Japan, 
indicate that the dose-repsonse curve is "different" in Japanese patients with 
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鹏 5 h Mean supine diastolic blood pressure (DBP) and heart rate (HR) in 
f hinese and Caucasians afer a single oral dose of perindopril 4 mg, perindopril 
4 mg/70 kg or cilazapril 2.5 mg. 
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essential hypertension (personal communication from Michael Egan, Medical 
Director, Roche, Hong Kong, no further information was made available to the 
author). W e have found a reduced effect on DBP, an indication of altered pressor 
responses (abolition of the rise in SBP in response to standing) and a significant 
increase in H R in Chinese subjects in response to ACE-inhibition. The existence 
of a genuine difference in the antihypertensive reponse to ACE-inhibitors is a real 
possibility which requires further, more intensive research. 
When one reviews the mass of evidence for a wide variety of factors that 
can influence both intra and inter-population drug metabolism, it seems quite 
uOnreasonable that so much of prescribing practice should be based on experience 
Ooften gained in only one racial population. It is distressing to find that many 
pharmacologists do not seem to take pharmacoanthropology into account and fail 
to mention the ethnic base of their population when reporting their kinetic 
findings. A quick perusal of the relevant literature shows that many commercially 
available drugs are tested only on Western Caucasian populations before being 
marketed throughout the world. It is clear that this situation is unsatisfactory from 
an Asian-Pacific standpoint. All affluent countries have become a veritable mixing 





The patient information sheet for the 
Cilazapril Study and the informed 
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r 
”weeing blood pressure which has been developed 
actf^n n extensively tested, and is relatively mild in its 
What Is the point： of thin gMn^y^ 
is k n o ^ that Chinese people break down some drugs differently from 
？ = 二 L n C . Sometijj^es this makes an alteration in dose n e c e s s a r y . y i ^ T 
important that we establish if this is the case with cilazapril. 
Where will the study take plurA? 
化 ^ f n stqUd/ be conducted in the Clinical Pharmacology Studies Unit 
(CPSU), 9 th Floor, Prince of Wales Hospital, Shatin. 
What will mv participation Involvft? 
The study lasts for 6 days. A preliminary medical examination and blood 
tests will be carried out initially to ensure that you are fit and healthy. 
If the results are normal, you may start the study within 10 days. 
THE NIGHT BEFORE YOU START THE FIRST DAY OF PART 1 TAKE NOTHING TO EAT OR 
DRINK AFTER 10 PM. 
Day 1 
1) Come to CPSU at 8.30 am on the morning of the trial, before having your 
breakfast (this is very important if we are to get accurate results). 
2) A doctor will put a small plastic tube (cannula) into one of your vein to 
make blood sampling easier and painless. After this a small amount of 
blood will be taken regularly for the rest of the day. 
3) You will then be given a standard dose of cilazapril in tablet form. At 
this stage you will begin collecting your urine. 
4) You will need to collect all the urine you pass during the six days of the 
first and second parts of the study. 
5) On the first day of each phase of the study you will need to stay in CPSU 
fo 12 hours. We realise that this may be very tedious for you and will 
provide radio, television and videos of your choice. We will attempt to 
be as entertaining as possible! Standard light meals will be provided 
whilst you are in CPSU. 
6) After the 12 hour sample has been taken your cannula will be removed and 
you can go home. 
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2 〉 a t / r ^ ； the 一 Mood s 一 抑d 
/^ re there any ri^V^ InvolvpH ^otng thl^ •”、， 
of/;>ctors. If at any stage you sta/t ^ ！:。feel u ^ l l S^e stuSy 
OPP”J^Mnediately. You may also withdraw from the project J o u r L i ? 
at any time, without giving a reason. ‘  yourseii, 
How about mv expenses? 
二 t 二 1/、, all travelling expenses which you incur as a result of the study 
！ ^ i h 1 y reimbursed. In addition, due to the inconvenience caused in this 
particular study, we think it fair to offer an extra §500 on completion 
* 
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• I 
Volunteer 
• it 二： ： y . ^ / n d e ^ a n d what is Involved and give my consent to participate 
. I r e ^ s r 命 s t a n d that I can withdraJ： .y consent ^ I ^ ' t S 
Signature of volunteer: 
Investigator 
I, hereby state that I have fully explained the nature, purpose and 
possible risks of participation in this research to the volunteer. 
Signature of Investigator: 
Dr. JAJH Critchley. 
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